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ABSTRACT
Colloss is a sterile extract of bovine bone matrix which consists predominantly of 
collagen type 1, but also contains several growth factors associated with bone matrix. 
The ability of Colloss to stimulate bone formation adjacent to titanium implants in vivo 
and its effect on the proliferation and differentiation of multipotential human bone 
marrow stromal stem cells (BMSSCs) in vitro and on titanium and hydroxyapatite 
(HA) was investigated.
When BMSSCs were cultured with a solution of Colloss in vitro for 21 days, evidence 
of osteogenic differentiation was signified by the expression of Alkaline Phosphatase 
(ALP), collagen type I, calcium deposition and changes in cell morphology.
When BMSSCs were cultured on titanium pre-treated with Colloss, there was increased 
expression of the osteoblastic markers ALP at day 7 and osteopontin on days 14 and 21 
compared to BMSSCs cultured on untreated titanium. BMSSCs cultured on porous 
hydroxyapatite pre-treated with Colloss showed no difference in the expression of the 
osteogenic markers ALP and osteopontin compared to BMSCCs cultured on untreated 
porous hydroxyapatite. However there was an increase in collagen type I synthesis, 
which was 3 times that of control cultures of BMSSCs on untreated HA at 21 days.
When Colloss was used to fill 1 and 2 mm defects adjacent to shot blasted titanium 
implants placed in tibia of sheep, there was no difference in the area of new bone 
formation or the degree of mineralisation of bone between the control and Colloss 
containing defects.
These findings show that Colloss can induce the osteogenic differentiation of bone 
marrow stromal stem cells cultured in monolayer and on smooth polished titanium. 
Results of BMSSCs cultured on hydroxyapatite were inconclusive, although evidence 
of collagen type I synthesis was suggestive of matrix deposition. Colloss did not 
enhance bone formation within defects adjacent to titanium implants in vivo.
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1.Introduction
The successful treatment of many orthopaedic conditions is dependent on the biological 
process of bone formation. Occasionally the biological bone healing response is 
insufficient and surgical intervention is required to promote formation of osseous 
tissue. For example, surgical intervention for the treatment of fracture non-unions often 
involves the placement of graft material at the fracture site. In other cases, the 
enhancement of bone formation is desirable to improve the stability of large load 
bearing orthopaedic implants. For instance, around failed hip replacements bone loss is 
common adjacent to the femoral stem resulting in periprosthetic defects. When this 
occurs, the technique of impaction bone grafting can be used to stimulate bone 
formation within these defects to enhance implant osseointegration and stability.1
Three fundamental factors which enhance bone formation are osteoinduction, 
osteoconduction and osteogenesis. Osteoinduction is the process by which there is 
stimulation of the differentiation of osteoprogenitor cells into osteoblasts and 
subsequent bone formation. Osteoconduction describes the ability of a substance to 
support the migration and proliferation of osteoprogenitors and osteogenicity signals 
the presence of bone forming cells.
Autologous bone graft has these three properties (osteoconductivity, 
osteoinductivity, osteogenicity) and is considered the gold standard graft material. It 
has an osteoconductive lattice structure comprising hydroxyapatite and collagen, and 
within its matrix are osteoinductive growth factors which stimulate osteogenesis.2 It is 
also osteogenic, containing cellular components comprising osteoblasts and osteoblast 
precursors which are required for osteosynthesis.
Unfortunately the use of autograft is associated with morbidity relating to the harvest 
site and increased surgical time. Furthermore its supply is limited and in certain
12
*3
procedures the amount of graft available may be insufficient. Younger et al reviewed 
the outcome of 239 patients undergoing bone grafting during orthopaedic procedures 
and found and overall complication rate of 8.6%. Complications included infection 
(2.5%), haematoma (3.3%), persistent pain (2.5%) and sensory loss (1.2%).
Allogenic bone graft, demineralised bone matrix and various synthetic bone graft 
substitutes have been used as alternatives to autologous bone graft, but in many cases 
have been less effective in promoting bony union.4,5,6 Whilst these alternatives may 
have osteoconductive and / or osteoinductive properties, when used without additional 
growth factors, they are less osteoinductive than autologous bone graft. Furthermore, 
they do not contain osteogenic cells required for bone formation and instead rely on 
migration of cells from the host at the site of implantation. In addition, with the use of
n
allogenic graft there is risk of disease transmission. For these reasons, there has been 
intense research to develop graft materials with improved efficacy.
In the clinical context, methods of generating osseous tissue would be valuable in 
any situation where bone formation is desirable. This would include the healing of 
fractures and fracture non-unions, the formation of bone within large long bone defects 
secondary to injury or disease and the fusion of spinal vertebrae 
Tissue engineering is a discipline in which cells, growth factors and biomaterials are 
utilised to repair or replace human tissue. The term “tissue engineering” was officially 
coined at a National Science Foundation workshop in 1988 to mean “the application of 
principles and methods of engineering and life sciences toward fundamental 
understanding of structure-function relationships in normal and pathological 
mammalian tissues and the development of biological substitutes to restore, maintain or
o
improve tissue function”.
The generation of viable tissues is based on strategies which utilise cells and growth 
factors in combination or independently and a suitable carrier. Crucial to the success of
13
any tissue engineering technique is the development of a suitable delivery system for 
the cells and growth factors utilised for the generation of tissue. For bone tissue 
engineering, carriers often take the form of biodegradable scaffolds which are based on 
collagen or polyglycolic acid.9,10,11 Ideally a carrier should have a capacity to hold and 
retain a large number of cells and or growth factors and have the structural integrity to 
withstand forces generated at the site of implantation. It should also be 
osteoconductive, promoting ingrowth of tissue at the host -  carrier interface. The 
carrier should gradually be resorbed and replaced by host tissue. In general, tissue 
engineering strategies for tissue repair and regeneration involve the generation of tissue 
in vitro for implantation, or the implantation of a material which induces the formation 
of the desired tissue in vivo.
1.1 Colloss (collagen lyophilisate)
Bone consists of cells and extracellular matrix. The extracellular matrix is 35% organic 
and 65% inorganic. The organic part is 90% collagen. The other 10% comprising 
osteocalcin, osteonectin, glycosaminoglycans and lipids. The inorganic part consists of 
calcium complexed with phosphate as hydroxyapatite. Bone matrix contains many of 
the growth factors involved in the cascade of bone formation. Bone matrix can be 
demineralised by treatment with hydrochloric acid to form demineralised bone matrix 
(DBM). The ability of DBM to induce new bone formation has been demonstrated in 
several animal studies.12,13’14 In humans it is often used as a graft for maxillo-facial 
reconstruction procedures.15,16
Colloss (collagen lyophilisate, Oberstenfeld, Germany ) is a sterile extract of bovine 
bone matrix. It is white and has a cotton wool consistency. There are several steps 
involved in the production process. First bovine bone undergoes a degermination 
(removal of cells) procedure involving treatment with hydrochloric acid and acetone. It
14
is then milled and under aseptic conditions undergoes decalcification and delipidation. 
The final product is obtained by an extraction process and then it is freeze dried. 
Colloss consists predominantly of collagen type 1, but also contains many of the 
osteogenic growth factors associated with bone matrix in a concentrated form. These 
factors include bone morphogenic proteins which can induce bone formation. Collagen 
type I is osteoconductive10 and has binding sites for cellular attachment.17 It can also 
promote calcium deposition by providing binding sites for mineral deposition and by 
binding non-collagenous proteins such as osteonectin and osteocalcin which promote
152calcium crystal deposition. Collagen also binds osteogenic growth factors. There are 
anecdotal reports of the use of Colloss to promote bone formation when used in clinical 
practice for the treatment of phalangeal cysts and for reconstructive maxillofacial 
procedures.
The ability of Colloss to enhance bone formation adjacent to implants was 
demonstrated in a study by Schlegal AK et al 2003. Ankylos dental implants coated 
with Colloss were placed in the frontal bones of pigs. In a further 2 groups of animals, 
implants were coated with platelet rich plasma or placed in an implant bed in which 
peri - implant bone had been condensed. In the control group there was no preparation 
of the implant or implant bed. Outcome measures were bone formation and bone 
density at the bone implant interface. At 2 weeks interface bone was greater in the test 
groups than the control group and the Colloss group was 60% compared to 30% in the 
control group. Similarly, at 4 weeks the Colloss group showed more implant interface 
bone than the control group, but by 6 weeks implant interface bone was similar 
between all groups. Bone density was greater in the Colloss group than control at both 
2 weeks and 8 weeks.19
In a further study by Wiltfang et al 2004, Colloss was implanted into critical sized 
defects in the skull bones of pigs.20 In comparison with an empty control defect, the
15
degree of reossification was 52.6% at 2 weeks compared to 38% in defects filled with 
autologous bone, 43.1% in Bio Oss (Bone substitute) filled defects and 32% in 
Cerasorb (bone substitute) filled defects. When BMP 2, which is expressed during early 
osteogenesis, was measured in the Colloss filled defects at 2 weeks, it was 7 times 
greater than in the surrounding bone. In a similar experimental model, Schlegel et al
i
found Colloss to be comparable to autologous bone for ossification of bone defects. 
The ability of Colloss to enhance bone formation in these experiments, without the 
addition of osteoprogenitors, suggests that it has a greater osteoinductive effect on local 
host cells than bone graft or bone substitute materials.
1.2. Bone marrow stromal stem cells (BMSSCs)
Bone marrow stromal stem cells are primitive cells present within bone marrow where
99they account for approximately 1 per 100,000 of the nucleated cells. They are 
multipotential, hence have the ability to differentiate along several lineage pathways to 
form a variety of tissue types including tendon, fat, muscle, cartilage and bone.23,24 
These properties raise the possibility of utilising such cells to repair skeletal tissues. As 
a result there has been intense interest in bone marrow stromal stem cells with 
investigation of their multipotential characteristics and behaviour in various cell culture 
environments.24'26
1.3. Titanium and the Osseointegration of Orthopaedic Prostheses
For several years titanium has been used for the manufacture of orthopaedic implants.
97 TO Pure titanium can be combined with other metals, such as vanadium and 
aluminium, to form titanium alloy. The alloy Ti-6%AL-4%V was initially developed 
for the aerospace industry, but now is used for the manufacture of orthopaedic
16
implants. The alloy is much stronger, with an ultimate tensile strength of 1170 Mpa 
compared to 220 Mpa for pure titanium.
Titanium and its alloys have physical and biological properties which are desirable.
Its physical properties are such that it is easy to machine into components, thus 
reducing the time and expense of implant manufacture. It has a modulus more similar 
to bone than other currently used implant alloys which, minimises the stress shielding
i
effects of the implant and reduces the associated bone resorption. This may reduce the 
risk of implant loosening and periprosthetic fractures. When exposed to oxygen, 
titanium reacts to form an oxide layer which provides protection from corrosion.
Unfortunately titanium alloys also display unfavourable characteristics which limit 
their application in orthopaedic practice. It has poor wear properties and hence is not 
routinely used as a bearing surface unless it has undergone surface modification. ’ ’
It is sensitive to notching, which can significantly reduce its fatigue strength, and there 
is also concern about the toxicity of titanium alloys used for prosthesis
'I*]
manufacture. ’
Loosening of the femoral component of total hip replacements limits the longevity of 
prostheses. Studies have shown radiographic loosening rates in uncemented prostheses 
of 2-27% at follow up of 5 to 13 years.38,39,40,41,42 The aetiology of loosening has been 
investigated in several studies. It has been demonstrated that a key factor in the 
loosening process involves the generation of polyethylene wear particles at the 
interface between the acetabulum and femoral head prosthetic components.43,44 These 
particles migrate down the cement -  bone interface or implant -  bone interface 
(uncemented femoral stems), where they are engulfed by macrophages. Particles less 
than 10pm can be phagocytosed by macrophages which respond to these particles by 
releasing a variety of inflammatory mediators, including interleukin lp, IL6, TNFa and 
PGE2, which stimulate bone resorption thereby accelerating the loosening
17
process.45,43,46,47’48,49 Eventually a fibrous membrane forms between the implant and 
bone. Therefore it is reasonable to propose that by creating a seal between bone and the 
implant, the migration of polyethylene wear particles can be prevented and the 
loosening process can be subdued.
In the field of maxillofacial surgery, considerable progress has been made in 
achieving osseointegration of titanium orthodontic implants.50,51 There has been less 
success in achieving the osseointegration of large functional orthopaedic prostheses, 
where the mechanical environment is more demanding. In an attempt to improve 
osseointegration, various modifications have been made to titanium alloys with mixed 
results. These include altering its chemical structure , making topographical changes 
or coating the implant surface with materials to improve bony ingrowth.
Variations in the surface roughness of titanium have been shown to influence the 
behavior of osteoblastic cells. 53,54,55,56 Shot blasting or sandblasting the surface of 
implants to create undulations in their surfaces can improve the osseointegration of
cn c o
titanium implants. ’
Coating titanium with certain materials has also been effective in improving bone 
ingrowth. These include hydroxyapatite, sintered beads and wire mesh. Hydroxyapatite 
is a bioactive material which has been shown to have osteoconductive properties. When 
used to coat titanium implants, it promotes bone ingrowth at the host implant interface. 
59,60,61 U n f o r t u n a t e l y  there are problems associated with the use of HA as an implant 
coating. Long term studies have shown that the function of HA is limited by 
compromise of bonding between HA and the implant, leading to delamination and 
resorption of the HA coating.62*64
18
1.4. Aim
The aim of this study is to investigate the osteogenic potential of Colloss on bone 
formation and to establish its effect on the behaviour of bone marrow stromal stem 
cells cultured in vitro. The effects of Colloss on the growth and differentiation of bone 
marrow stromal stem cells cultured in vitro was investigated in monolayer and on 
titanium and hydroxyapatite biomaterials. An in vivo study was then performed to 
assess the effect of Colloss on bone formation within defects adjacent to titanium alloy 
implants placed in sheep tibia.
1.5. Hypotheses
1. Colloss will stimulate the osteogenic differentiation of bone marrow stromal 
stem cells cultured in monolayer and on titanium and hydroxyapatite 
biomaterials.
2. Colloss can stimulate bone formation within defects adjacent to titanium 
implants enhancing their osseointegration.
19
2. LITERATURE REVIEW
2.1. History
The use of cells for the purpose of healing bone was documented more than 300 years 
ago, in 1668 by Job Van Meek’ren. Two hundred years later in 1869, Gougon, 
described the osteogenic potential of bone marrow.65 In more recent times bone marrow 
has been used successfully as a graft material to heal tibia, scaphoid and humeral 
fracture non-unions.66-68,69,70 In 1991 Connolly described the use of bone marrow as an 
alternative to bone graft for the treatment of non-unions. In Connolly’s study the 
healing of 18 of 20 ununited tibia fractures was achieved by injecting bone marrow
71aspirates directly into the fracture site.
Direct evidence of the presence within bone marrow of cells with osteogenic 
potential was provided by Friedenstein in 1966 who showed that in a diffusion chamber
79single cell marrow suspensions could form mineralised bone. Further evidence to 
support the existence of osteoprogenitor cells within bone marrow was provided in
7 0  nc
experiments by Friedenstein and Ashton, - who demonstrated that guinea pig and 
rabbit marrow fibroblast cultures formed bone when transplanted into diffusion 
chambers. It was later proposed that osteoprogenitors within the bone marrow were 
derived from stromal stem cells which have the potential to differentiate into several
9^cell types to form mesenchymal tissues.
More recently, studies have demonstrated that within bone marrow there are cells
7 f\ 77 70capable of differentiating to form adipocytes, chondrocytes and bone. Athough it 
had been demonstrated that there were cells within bone marrow which could 
differentiate to form several cell types, it was unclear as to whether such tissues 
originated from a true multipotential stem cell or were the product of several different
9*>
progenitors. In 1999 Pittenger et al performed a study which gave strong support to
20
the presence of a true mesenchymal stem cell. Bone marrow stromal stem cells 
(BMSSCs) were isolated from human donors and cultured in monolayer. Individual 
cells were identified in culture and grown to form colonies. Colonies, which had 
therefore originated from one single cell were expanded in culture, then using media 
supplements were stimulated to differentiate along lineage pathways to form 
adipocytes, chondrocytes and osteocytes.
Stem cells by definition are undifferentiated, self replicating and multipotential.
The presence of bone marrow stem cells with such properties means there is great 
potential for the regeneration of skeletal tissue and thus the treatment of patients 
suffering from disease or injury.
2.2. Bone marrow stromal stem cells
TO fiO 81 fiOMesenchymal stem cells can be found in muscle, ’ periosteum ’ and adipose
• OO O A  1 Of
tissue ’ ’ ’ but are most commonly obtained from bone marrow (bone marrow 
stromal stem cells) because of the ease of harvest. Bone marrow stromal stem cells 
(BMSSCs’) are the precursors of osteoprogenitors. After skeletal maturity the number 
of osteoprogenitors within bone marrow decreases. This was demonstrated by Nishida 
et al 1999. The presence of osteoprogenitors was determined by quantifying Alkaline 
Phosphatase expression. It was found that although the ability of bone marrow stromal 
stem cells to form osteoblasts was maintained with advancing age, there was a marked 
drop in number of these cells after the first decade of life, followed by a more gradual 
decline after age twenty. 86 D’ippolito et al 1999 came to a similar conclusion from the 
examination of vertebral bone marrow.87 It is possible that these observations are a 
contributory factor in the age related reduction in the capacity of fractures to heal and 
may also be a mechanism for senile osteoporosis.
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Following harvest, BMSSCs can be expanded in culture and passaged up to 38 times
• • • • • oo #without loss of phenotype or ability for multipotential differentiation. BMSSCs in 
culture have been differentiated in vitro to form adipocytes, chondrocytes, fibroblasts 
and osteoblasts by the addition of supplements to growth medium. The osteogenic 
differentiation of bone marrow stromal cells has been achieved using dexamethasone, p
9^ 78glycerol phosphate and ascorbate. ’
2.3. Clinical application of stem cells
Following expansion of cells in culture, there are several options with regards to how 
they are utilised to generate skeletal tissue. They can be delivered to a skeletal site as a 
cell suspension or combined with a carrier material. Growth factors can be used to 
stimulate the differentiation of mesenchymal stem cells along desired lineage pathways 
prior to implantation, or can be applied to cells at the time of implantation. However 
many growth factors are short acting and when delivered in vivo their biological 
activity may be of insufficient duration to achieve effective healing. To overcome this 
problem gene therapy has been utilised in studies to produce bone marrow stem cells
o n  QA
which can express specific growth factors. ’ Mesenchymal stem cells have been used 
to repair tendons, and heal articular cartilage and long bone defects.91,9,92
2.3.1. Cartilage defects
Wakitani et al 1994 used mesenchymal stem cells harvested from the bone marrow and 
periosteum of rabbits to heal articular cartilage defects 91 Cells were expanded in 
culture then dispersed in a collagen gel prior to implantation into large cartilage defects 
on the weight bearing surface of rabbit femoral condyles. In control animals defects 
were left empty. At 2 weeks implanted osteoprogenitor cells had differentiated into
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chondrocytes and at 24 weeks the tissue in the cell filled defects was stiffer than that of 
the empty defects but less stiff than the normal cartilage.
2.3.2. Tendon
Young et al 1998 used mesenchymal stem cells to heal defects in rabbit Achilles 
tendons.9 Mesenchymal stem cells were aspirated from bone marrow, expanded in 
culture, and then suspended in a collagen gel which was loaded onto a suture prior to 
implantation within the tendon defect. In the control group tendon gaps were filled only 
with suture material. Tendons were evaluated histologically and biomechanically at 4, 8 
and 12 weeks. At all three time intervals, the cross sectional area of the treated tendons 
was significantly greater than the control group. At 4 weeks tendon stiffness in the 
treated group was 54.2% of normal tendon and twice that of control tendon. These 
values remained constant to the 12 week end point of the study. On histological 
examination repair tissue in the experimental group consisted of organised bands of 
collagen similar to tendon fibroblasts. In contrast, control specimens showed a variable 
morphology.
In both these studies bone marrow stromal cells differentiated into location specific 
tissue without the addition of growth factors. This suggests that local environmental 
signals play a role in determining the differentiation lineage pathway.
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2.3.3. Bone formation
Bone formation is a complex process which involves the differentiation of cellular 
precursors into osteoblasts and osteocytes with the formation of mineralised matrix. 
During the cascade of osteogenesis, bone marrow stromal stem cells differentiate to 
form osteoprogenitors, then pre-osteoblasts and finally osteoblasts. During this process 
there are changes in cellular activity. There is an early phase of cell proliferation which 
is followed by matrix synthesis by osteoblasts. In the early phase of matrix synthesis, 
unmineralised osteoid accumulates. Later, calcium accumulates and forms complexes 
with phosphate resulting in matrix mineralisation. During the process of osteogenesis 
certain markers of osteoblastic differentiation are expressed. These include alkaline
1 ftphosphatase, collagen type 1, osteocalcin, osteonectin and osteopontin. These markers 
can be quantified in vitro, allowing investigators to monitor the osteogenic process.
The utilisation of BMSSCs to stimulate bone formation has been of particular interest 
because it may provide a means of enhancing new bone formation, providing an 
alternative to autologous bone graft. Bone marrow stromal stem cells have been used in 
animal studies to heal segmental long bone defects in animals. Bruder et al, 1998, 
created 21mm long segmental defects in canine femora. In the experimental group, 
defects were filled with porous ceramic cylinders which had been loaded with 
autologous culture expanded mesenchymal stem cells. In the control group, defects 
were filled with porous ceramic cylinders alone. At sixteen weeks animals were killed 
and specimens harvested for examination. In the control group, all femora went on to 
non-union. In contrast all the defects treated with BMSSC loaded ceramics formed a 
collar of new bone surrounding the implant and had united radiographically by 16 
weeks. In other studies BMSSCs have been used successfully to heal segmental defects 
in the rabbit radius and rat femur.
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2.4. Growth Factors involved in the cascade of bone formation
Growth factors are small protein molecules which interact with cell surface receptors to 
influence cell behaviour. During the process of tissue formation, growth factors 
influence cell proliferation, differentiation and matrix production (fig.l). Several 
growth factors which are involved in the cascade of bone formation have been 
identified and their properties investigated. These include fibroblast growth factor 
(FGF), insulin like growth factor (IGF), platelet derived growth factor (PDGF) and the 
transforming growth factor beta (TGFp) superfamily which includes the bone 
morphogenic proteins (BMPs).
2.4.1. Transforming growth factor Beta (TGF P)
Transforming growth factor p(TGF p) is believed to play an important role in bone 
growth and repair. This is supported by the positive immunostaining of TGF p in 
fracture callus during the healing process.94 TGF p is a sulphydryl bonded dimeric 
molecule, of which there are 5 isoforms. It is present in chondrocytes, platelets, 
osteoblasts and mesenchymal stem cells and is secreted in the form of a propeptide 
which is enzymatically cleaved to release the active molecule. On secretion, TGF p is 
sequestered by a binding protein which modulates its interaction with receptors. All 
forms of TGF p interact with cells via type I and II receptors. TGF p receptors are 
serine / threonine kinases and on activation, their effects on the target cell nucleus are 
mediated by intercellular proteins called SMADS. The effects of TGF p on 
mesenchymal stem cells has been studied in vitro. Cassiede et al investigated the 
effects of TGF pi on alkaline phosphatase expression, cell proliferation and 
osteochondrogenic potential of pre-confluent rat mesenchymal stem cells.95 In the 
experimental group MSCs were cultured with TGF pi 5ng/ml for 48 hours. Non­
treated mesenchymal stem cells were used as controls. Mesenchymal stem cells pre-
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treated with TGF (51 showed increased proliferation rates when compared to the control 
group. However, Alkaline phosphatase levels were lower in the TGF (51 pre-treated 
group. Pre treated and control MSCs were then either cultured in osteogenic medium or 
seeded onto porous calcium phosphate and implanted subcutaneously in synergeic rats. 
Assay for in vitro nodule formation indicated that TGF pi inhibited bone formation. 
However, in vivo it supported the formation of cartilage and bone.
In vivo, the effect of TGF p on the repair of bone has been studied in animal models. 
Nielsen et al 1994 injected TGF p at a dose of 4 or 40ng around the fracture site of 
healing rat tibia fractures.96 The 4ng dose had no effect on bone strength when 
compared to the placebo, however rat tibia injected with 40ng TGF p had a higher 
ultimate load and increased amount of bone formation at the fracture site. Lind et al, 
1993, 97 examined the effects of TGF p on the healing of tibial defects in rabbits. TGF 
p was applied at doses of 1 and 10 micrograms per day in 2 groups of rabbits with 
plated mid tibial osteotomies. TGF P resulted in an increase in bending strength and 
callus formation, but no effect on bending stiffness, bone mineral content, cortical 
thickness or Haversian canal diameter. The authors concluded that TGF p enhanced 
fracture healing in rabbits.
2.4.2. Bone Morphogenic Proteins (BMP)
In 1965 Urist described the osteoinductive properties of demineralised bone matrix. In 
his initial experiment, bone formation was stimulated by the implantation of
QQ #
demineralised bone matrix into subcutaneous pouches in rats. Later, the proteins
responsible for the osteoinductive properties of demineralised bone matrix were
identified and called the bone morphogenic proteins (BMPs). They are a group of 15
low molecular weight glycoproteins which belong to the TGF p superfamily. Unlike
TGF p, they are secreted in the active form. They have ligands for the type I and II cell
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surface receptors. When BMPs interact with type I receptors, type 2 receptors bind 
with and phosphorylate the type 1 receptor. This interaction and the resulting complex 
results in phosphorylation of intracellular SMAD proteins, which are involved in 
intracellular signal transduction."
The bone morphogenic proteins stimulate the differentiation of mesenchymal stem 
cells along osteochondrogenic pathways to form bone. They play an important role in 
the induction of bone formation during fracture healing. The identification of the 
genetic sequence for BMP has allowed its synthesis in vitro using recombinant gene 
technology. 100 There has been intense interest in the bone morphogenic proteins since 
they were discovered, and many animal studies have been performed to assess their 
ability to stimulate bone formation and heal skeletal defects in vivo and in vitro. Itoh et 
al, 1998, investigated the ability of human recombinant BMP 2 to heal segmental long 
bone defects in dogs.11 Two centimetre defects were created in bilateral ulnae of 8 
dogs. The defect was plated then filled with a poly D, L lactic -  co-glycolic acid 
(PGLA)/gelatin sponge complex (PGS) carrier, either alone or in combination with 
40pg, 160pg or 640pg recombinant BMP 2. There were 4 ulnae per treatment group. 
Twelve weeks postoperatively all defects treated with 160pg and 640pg BMP 2 
showed radiographic evidence of union. The group treated with 40pg showed bone 
formation but no healing, and the control group treated with carrier alone did not 
demonstrate any evidence of healing. Bone mineral content at 16 weeks was 
significantly higher in the groups treated with 640pg and 160pg BMP than the defects 
filled with 40pg BMP 2 or PGS carrier alone. Cook et al 1995 investigated the healing 
of ulna and tibial defects in monkeys using OP 1 (BMP 7).101 Ulna defects were filled 
with either lOOOpg of OP 1 combined with carrier, autologous bone graft or carrier 
alone. Five of the six ulnae treated with OP 1 had healed radiographically at 6 to eight 
weeks, whereas none of the group that received the carrier alone or autologous bone
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graft showed evidence of complete healing. On mechanical testing, ulnae treated with 
OP 1 had a torsional strength which was 92% that of the contralateral ulnae, whereas 
ulnae treated with autologous bone graft had insufficient healing and therefore could 
not be mechanically tested.
2.4.3. BMPs in humans
BMP 2 and BMP 7 have recently gained approval from the FDA (United States, food 
and drug administration) and are currently licensed for use in humans as an alternative 
to autologous bone graft in spine surgery and to treat long bone non-unions 
respectively. Results of early trials using BMP 2 in spinal surgery have been promising. 
When used as a graft for the lumbar and cervical spine, fusion rates were comparable
•  1 ( i ' jwith those of autologus bone graft.
2.4.4. Insulin like growth factor (IGF)
There are 2 types of insulin like growth factor. These are IGF I and IGF II. IGF I 
mediates many of the functions of growth hormone and is involved in osteoblast and 
chondrocyte proliferation, differentiation and matrix formation. IGF II is involved in 
the growth of foetal tissue and the differentiation of osteoblasts and chondrocytes. 
Trippel et al, 1993, demonstrated the stimulatory effect of IGF I on chondrocytes
1 A3from the distal radial growth plates of calves. Proliferation was measured by 3H 
thymidine incorporation and matrix production by 35S-sulphate incorporation into 
glycosaminoglycans. IGF I was shown to increase thymidine incorporation by 2.5 X 
control cultures and increase 35S sulphate incorporation by 2.6 X control cultures. 
Scheven et al, 1991, examined the effects of recombinant IGF I and II on human 
osteoblast cells derived from femoral heads and found both to have a stimulatory effect 
of osteoblast cell growth.104 In vivo, circulating insulin like growth factor is bound to
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IGF binding proteins, of which there are six. They act, not only to transport IGF to 
target tissues but also have a role in determining the bio availability of IGF. There is 
also evidence to suggest that IGF Binding proteins may act independently as growth 
factors to stimulate bone formation.105
OSTEOGENESIS
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Fig.l. Substances which influence cell proliferation and differentiation 
during osteogenesis
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2.4.5. Platelet Derived Growth Factor (PDGF)
Platelet derived growth factor is a glycoprotein which is released from platelets and 
mesenchymal cells. It has been shown to stimulate osteoblast proliferation in vitro and 
bone formation in vivo, and is believed to be involved in fracture healing, although its 
precise role has still to be clearly defined. Vikjaer et al, 1997,106 investigated the ability 
of recombinant PDGF to heal calvarial defects created in 16 rats. Eight defects were 
filled with a methylcellulose gel combined with recombinant PDGF. In the control 
group, defects in 8 rats were filled with methylcellulose gel alone. Bone formation was 
evaluated at 8 weeks. It was found that PDGF stimulated more bone ingrowth with a 
higher mineral content than the control group. Also, bone in the PDGF group formed a 
trabecular structure compared to a more compact structure in the control group. PDGF 
may have a role in the mechanically induced healing of fractures. Wang et al, 1997, 
found that strain induced proliferation of osteblasts was also associated with increased
107production of PDGF-A. Furthermore, antibodies against PDGF-A inhibited 
mechanically induced proliferation of osteoblasts. This would suggest that PDGF has a 
contributory role in the response of osteoblasts to mechanical stimuli.
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2.4.6. Fibroblast growth factor (FGF).
Fibroblast growth factors (FGFs) belong to a family of nine structurally related 
polypeptides. They interact with the cell surface receptors of a variety of cells, 
including osteoblasts, chondrocytes, epithelial cells and myocytes. The most common 
types of FGF found in humans are FGF-1 and FGF-2. There are 4 cell membrane 
spanning receptors through which FGF interacts to influence cell function. The effects 
of FGF have been studied in vitro and in vivo. Kato et al 1998 made 3mm segmental 
defect in the tibia of rabbits, which were then injected with recombinant FGF-2 in 
varying concentrations. At 5 weeks bone formation within the defects was examined. 
At concentrations of lOOpg and above FGF-2 increased bone volume and mineral 
content in the defects.
Nakamura T et al 1998 investigated the effects of FGF-2 on fracture healing in dog
i notibia. Transverse fractures were created in dog tibiae. In the experimental group 
fractures were injected with 200pg of FGF-2. At week 4 the FGF-2 injected fractures 
had a greater amount of callus and at week 8 a greater bone mineral content than the 
control group. At weeks 2 and 4 FGF-2 also resulted in an increase in the number of 
osteoclasts in the periosteal callus. The authors concluded that FGF-2 promotes both 
fracture healing and remodelling.
The effect of FGF-2 on fracture healing in primates has also been investigated. 
Radomski, et al injected a single dose of FGF-2 combined with hyaluronan into 1mm 
osteotomies in the fibulae of baboons.110 The callus area was significantly greater in the 
treated than non-treated fracture sites. On histological analysis, fracture sites treated 
with FGF 2 showed a greater vascularity, periosteal reaction and cellularity. These 
studies suggest that fibroblast growth factors have properties which enhance fracture 
healing.
31
2.5. Summary
Osteogenesis is a complex process involving the differentiation of bone marrow 
stromal stem cells into osteoblasts with the formation of mineralised matrix. The 
behaviour of osteoprogenitors is influenced by several growth factors which have been 
shown to have specific effects on cellular activity in vivo and in vitro. The process is 
further influenced by cell -  matrix and cell -  cell interactions. Local tissue specific 
signals play a role in determining the subsequent differentiation of stromal stem cells 
implanted in skeletal sites. Investigation of the effects of osteogenic substances on the 
growth and differentiation of bone marrow stromal stem cells is important for the 
development of tissue engineering techniques to regenerate skeletal tissues.
Colloss is derived from bovine bone and contains several bone matrix associated 
growth factors. The availability of a variety of such factors may confer an advantage by 
allowing the stimulation of osteogenesis at several intermediate stages of 
osteoprogenitor differentiation. Preliminary studies investigating its osteogenic 
potential have been promising, but further investigation is required to obtain further 
data in relation to its effect at the cellular level, and its potential for use in clinical 
orthopaedic practice.
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3. Chapter 1
Investigation of the Effects of Colloss on the Osteoblastic 
Differentiation of Human Bone Marrow Stromal Stem Cells
3.1. Introduction
Tissue engineering techniques utilising BMSSCs have been investigated as a means of 
regenerating, replacing and repairing musculoskeletal tissues. To date MSCs have been 
used to enhance tendon repair, fill cartilage defects and stimulate bone formation within 
skeletal defects with variable success.111,112'114, 25 The processes involved in the 
differentiation of BMSSCs along lineage pathways is incompletely understood, but is 
believed to be regulated by complex intra and extracellular signalling pathways. 115,99, 
ii6,ii7 jkg formation 0f  mineralised matrix, following the differentiation of BMSSCs 
into osteoprogenitors has been demonstrated in tissue culture systems. Osteopontin, 
alkaline phosphatase and procollagen are expressed during osteogenic lineage 
progression of BMSSCs and can be used as markers of osteogenic differentiation.
95,118,119
The osteoinductive properties of various growth factors have been examined using 
BMSSC culture systems. Substances which have been shown to be osteoinductive 
include the bone morphogenic proteins and fibroblast growth factor.116,120
Cottoss (Collagen lyophilisate)
Colloss (Collagen lyophilisate) is a sterile extract of bovine osteoid matrix which 
contains collagen type 1. It is available in a solid form which has a cotton wool 
consistency and as a liquid suspension. It contains several cytokines which act at 
various steps in the cascade of osteogenic differentiation. In clinical studies, the solid
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preparation has been used to fill and stimulate bone formation within phalangeal cysts 
and maxillofacial defects. To date no studies have been published which examine the 
effects of collagen lyophilisate on bone marrow stromal stem cells.
3.2. Aim and Hypothesis
Aim - To investigate the ability of Colloss to stimulate the osteogenic differentiation 
of adult bone marrow stromal stem cells (BMSSCs) in vitro.
Hypothesis - Colloss can stimulate the osteogenic differentiation of bone marrow 
stromal stem cells (BMSSCs) in vitro.
3.3. Materials and Methods
3.3.1. Harvest of bone marrow and isolation of stromal stem cells
Approval for this procedure was obtained from the Royal National Orthopaedic 
Hospital Ethics Committee and informed consent was obtained from the human bone 
marrow donor. Bone marrow was aspirated from a donor who was under general 
anaesthesia for an elective orthopaedic surgical procedure. The skin overlying the iliac 
crest was prepared and draped, then through a short skin incision bone marrow was 
aspirated using a bone marrow aspiration needle attached to a 10mm heparinised 
syringe.121 All bone marrow stromal stem cells used in this study were derived from a 
single donor.
Mesenchymal stem cells were isolated from the bone marrow using the Ficoll 
Density gradient technique.122,78 Bone marrow was loaded onto Ficoll-Hypoaque® 
(Amersham Pharmasin Biotech 75285, density gradient 1.077g/ml) within a universal 
container and centrifuged at lOOOg for 30 minutes. Bufify coats containing the BMSSC 
enriched low density fraction were isolated and resuspended in medium comprising 
Dulbecco’s modified Eagles medium (4500mg/L glucose/L, L-glutamine and sodium
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pyruvate, Sigma Aldrich D6429), with 1% Penicllin / Streptomycin. (Sigma-Aldrich Co 
Ltd, Irvine UK) and 10% bovine foetal calf serum (FCS) and centrifuged for 5 minutes 
at 2000g. Supernatant was removed and pelleted cells were resuspended in medium by 
3 successive aspirations and expulsions through a 23-gauge needle attached to a 5 
millilitre syringe. Cells were counted using a Neubauer counting chamber and plated at 
a density of 2x10 cells/cm into culture flasks (Falcon, Becton Dickinson Lab ware, 
Europe). Cells were then cultured with medium and incubated at 37°C in 95% air with 
5% carbon dioxide at 100% humidity.
3.3.2. Cell Passage
Once cells had reached approximately 80% confluence, they were subcultured by the 
following steps. Culture medium was removed and trypsin (sterile filtered solution. 25g 
porcine trypsin per litre in 0.9% NaCl. Sigma-Aldrich Co Ltd, Irvine UK) was added to 
the culture flask, which was then incubated for 5 minutes at 37°C in 95% air and 5% 
carbon dioxide at 100% humidity resulting in detachment of cells. The flask was then 
rinsed with 5 mis of medium twice and rinsings were transferred to a universal 
container and centrifuged at 2000 rpm for 5 minutes. Supernatant was removed and 
pelleted cells were resuspended in 2mls of medium. A further 8 mis of medium was 
added to the cell suspension, which was then transferred into 175 cm2 culture flasks ( 
Falcon, Becton Dickinson Lab ware, Europe) and supplemented with medium. Cells 
were expanded in culture by serial passage on reaching confluence. Cells between 
passage 5 and 7 were used for all experiments.
Total DNA, proliferation,. Alkaline Phosphatase activity, Collagen type 
1 (procollagen carboxy terminal peptide) and Osteopontin were measured in cells which 
were cultured in 6 well plates. For these experiments 3xl04 mesenchymal stem cells 
were seeded into wells at a, density of 3000 cells/cm2 . Each well was then filled with
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2mls of standard medium (control group) or 2mls of medium containing collagen 
lyophilisate (Colloss dispersion, concentration 1.4d.m./ml, Ossacur AG) diluted 1:50 or 
1:100. All cultures were performed in triplicate.
3.3.3. Characterisation of bone marrow stromal stem cells with STRO-1 
IgM monoclonal antibody.
In this study the presence of Stro -1 cell surface marker was used to confirm that cell 
cultures comprised a multipotential bone marrow stromal stem cell population. STRO-1 
is a cell surface antigen expressed by a subpopulation of bone marrow stromal cells 
capable of differentiation along several lineage pathways. Previous studies support the 
use of STRO-1 antigen as a stem cell surface marker. It has been demonstrated that 
bone marrow stromal cells positive for the STRO-1 antigen maintain an immature pre- 
osteoblastic phenotype and have the ability to differentiate into a variety of stromal cell 
types including adipocytes, chondroblasts and chondrocytes.123,124
Cells expressing the Stro -1 cell surface marker were identified using an indirect 
enzyme linked immunofluorescent antibody method. 3xl04 bone marrow stromal stem 
cells were seeded onto sterile cover slips (Falcon ™). One coverslip with cells was 
placed into each well of a six well culture plate. Wells were supplemented with control 
medium containing Dulbecco’s modified Eagles medium (lOOOmg glucose/L, L- 
glutamine, NaHCOs and pyridoxine.HCL), with 1% penicillin / streptomycin. (Sigma- 
Aldrich co LTD, Irvine UK) and 10% bovine foetal calf serum (FCS). At 36 hours 
cells were washed 5 times with Dulbecco’s phosphate buffered saline (Sigma D8537). 
Cells were then incubated in medium containing STRO-1 monclonal antibody (IgM 
mouse anti STRO-1, University of Iowa, Iowa city, IA 52242, USA.) diluted 1:20 for 1 
hour at 37 °C in 95% air and 5% carbon dioxide at 100% humidity. Medium was then 
removed from the wells and cells were given a further 5 washes with phosphate
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buffered saline, before incubation for 1 hour with anti mouse IgM-FITC monoclonal 
antibody (F9259 Sigma-Aldrich Co. Ltd, Irvine, UK) at a concentration of 1:128 in 
control medium. After the incubation period cells were mounted onto slides and 
observed using an Olympus BH-2 -  RFCA microscope under fluorescent light.
3.3.4. Histological staining of mesenchymal stem cells in monolayer
3.3.4.1. Alizarin red
Mesenchymal stem cells were seeded onto 6 well plate culture dishes at a seeding 
density of 3xl03 cells/cm2. In the control group, each dish was supplemented with 2 
mis of standard medium comprising Dulbecco’s modified Eagles medium (lOOOmg 
glucose/L, L-glutamine, NaHC0 3  and pyridoxine.HCL), with 1% penicillin / 
streptomycin. (Sigma-Aldrich Co Ltd, Irvine UK) and 10% bovine foetal calf serum 
(FCS).
In two experimental groups, the standard medium was replaced with medium 
supplemented with collagen lyophilisate at concentrations of 1:50 and 1:100. Cultures 
were incubated at 37°C in 95% air and 5% carbon dioxide at 100% humidity and 
stained for the presence of mineralised matrix with Alizarin Red on days 4, 8, 16 and
17521 by the following procedure, which has been described by Stanford. Medium was 
removed from the wells and the cell layer was washed with Dulbecco’s phosphate 
buffered saline (Sigma-Aldrich Co. Ltd, Irvine KA12 8NB, UK) and then fixed by the 
application of 70% ice cold alcohol for 1 hour. Cells were then rinsed with distilled 
water five times and washed for 15 minutes in phosphate buffered saline to remove 
non-specific stain. Cultures were then air dried and photographed using a Nikon FE 
camera with a Nikon 60mm macro lens and 35mm Fujichrome 64 T Type II 
professional color reversal film ISO 64/19°.
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3.3.4.2. Alkaline Phosphatase
Sterile 22mm x 22mm glass coverslips (Chance Propper Ltd, Smethwick, Warley,
England) were placed in the wells of a 6 well culture plate. 3xl04 BMSSCs were
seeded onto each coverslip and 2mls of either standard medium or medium containing
Colloss 1:50 or 1:100 was placed in each well. Cells were stained for the expression of
1Alkaline Phosphatase using a method described by Stutte.
The incubating media was prepared as follows: a buffer was prepared by the addition 
of lOmls of 0.2M Tris to 0.1 M HCL made up to 40mls with distilled water. The pH of 
the buffer solution was then adjusted to 9.0 by the addition of 0.1 M Hydrochloric acid 
as required. The incubating medium was completed by the addition of lOmg Napthol 
AS B1-Phosphate, 8 drops of 4% new fuschin in 2M HCL and 8 drops of 4% sodium 
Nitrite.
At 4, 8, 16 and 21 days medium was removed from the culture wells and cell layers 
were rinsed with phosphate buffered saline, following which cells were fixed with 10% 
formal saline. The incubating medium was pipetted onto the incubating dish and 
incubated at 37° C for 30 minutes. Incubating medium was then removed and 
coverslips were washed in distilled water for 2 minutes, rinsed and drained. Methyl 
green counter stain was added for 2 minutes. Coverslips were then air dried and 
mounted with pertex coverslip mounting medium. The presence of cells expressing 
Alkaline Phosphatase is signified by pink staining of cells.
3.3.5. Cell proliferation assay using alamar™ blue Assay
Alamar blue was used to measure cell proliferation. It is a dark blue dye containing an 
oxidation -  reduction (REDOX) indicator, which when taken up by cells becomes 
reduced to a red colour which fluoresces. The amount of fluorescence can be quantified 
by measuring absorbance. The degree of conversion relates to the viability of cells and
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their ability to metabolise alamar blue. Its measurement can therefore give a measure of 
cell number and over time a measure of cell proliferation. A linear relationship between 
fluorescence and cell number has been shown and some authors have found it to be
107comparable to thymidine incorporation assays for measurement of cell proliferation. ’
128
Cellular proliferation was measured using a technique adapted from Nakayama et al,
1 *701997. Cell proliferation was measured on days 3, 9, 14 and 21 by the following 
technique. Medium was removed from the wells of the 6 well plate and replaced with 2 
millilitres of alamar blue diluted 1:10 in the cell media. Cells were then incubated for 4 
hours at 37° C, humidity 100%, 5% CO2. Two lOOpl aliquots were then removed from 
each well and transferred to a 96 well plate.
Absorbance was measured at 595nm with a reference wavelength of 655nm using a 
Biorad microplate reader (model 3550, Bio-Rad Laboratories Ltd , Hemel Hempstead, 
Hertfordshire HP27TD). Analysis was performed in triplicate cultures. Culture of cells 
was continued by removing the remaining alamar blue contained medium from the 
wells and replacing it with either standard medium in the control groups or collagen 
lyophilisate containing medium in the experimental groups.
39
3.3.6. Total DNA using Hoescht 33258
Total DNA was measured on days 3, 7,14 and 21 using a technique described by Rago 
et al, 1990.130 The fluometric dye, Hoechst 33258, is DNA specific and binds to 
contiguous adenine-thymine base pairs emitting fluorescence at a wavelength of 
460nm.
3.3.6.1. Cell lysis using freeze thaw cycle
Medium was removed from culture plate wells of the experimental and control groups 
and replaced with 2 mis distilled water. Cell lysis was achieved by a freeze thaw cycle. 
The culture plate containing cells was cooled to -70° C for 20 minutes followed by 20 
minutes in a warm room at 37° C for 20 minutes. This cycle was repeated once.
3.3.6.2. Preparation of a standard curve
DNA 1 mg/ml from calf thymus was used as a standard (Sigma D3664). This was 
diluted 1:50 in saline sodium citrate buffer to give a solution of concentration 20pg 
DNA per ml of buffer. This solution was sequentially diluted 1:2 to provide standards 
of 20, 10, 5,2.5, 1.25, 0.63 and 0.31 pg/ml of buffer.
3.3.6.3. Preparation of Buffer
The buffer was made by adding 43.825grams of sodium chloride and 22 grams of 
Trisodium citrate to 480 mis of purified water. The pH was adjusted to 7.0 with 1M 
sodium hydroxide or 1M hydrochloric acid as required and the solution was made up to 
500mls. Buffer was then sterilized by autoclaving. This buffer solution was diluted 
1:20 for use in this procedure.
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A lOOpl sample of the distilled water used in the freeze -  thaw cycle was transferred 
from each culture well plate in duplicate to the wells of a 96 well plate (Falcon TM). 
lOOjul of Hoechst diluted to 1 pl/ml of saline sodium citrate buffer was also added to 
each well Fluorescence was measured at 460nm using a  flurometer (Ascent reader, 
Labsystems). Analysis was performed using windows based Genesis software package.
3.3.7. Alkaline Phosphatase assay
Alkaline Phosphatase was measured on days 3, 7, 14 and 21 using a technique adapted 
from that described by Oreffo et al.119 This method is based on the principle that the 
enzyme Alkaline Phosphatase cleaves the phosphate group from p-nitrophenol 
phosphate, resulting in the release of p-nitrophenol which has a yellow colour at 
alkaline pH and can be monitored at 405nm. The Cobas Bio analyser (Roche 
diagnostics, Welwyn Garden City, UK) calculates the results using the reaction rate 
method by which a series of readings are taken and plotted against time to provide a 
slope, which indicates the rate of appearance of the colour which correlates with 
Alkaline Phosphatase activity.
Medium was removed from wells and replaced with 2mls of distilled water. Cells 
were lysed to release ALP using the freeze-thaw cycle described previously. A 50pl 
sample of distilled water was taken from each well, from which ALP activity was 
analysed using the Cobas Bio. Precinorm U (Roche Diagnostics Ltd, Lewes, East 
Sussex UK) control serum used for calibration and was analysed with each assay to 
ensure quality control.
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3.3.8. Calcium mineral content using Alizarin Red-S assay.
Calcium mineral content of cell layers grown in control medium and medium 
containing Colloss concentration 1:50 was measured with an Alizarin red-S assay using 
methods described by Stanford et al, 1995.125 Alizarin red -  S (AR-S) is a dye which
94-binds selectively to calcium salts. Each 1 mol of AR-S binds to 2 mols of Ca .
Bone marrow stromal stem cells were seeded into 25cm culture flasks (Falcon, 
Becton Dickinson Lab ware, Europe) at a density of 30,000 cells per flask. One group 
was supplemented with standard control medium and the other with standard medium 
containing Colloss diluted 1:50. Calcium mineral content was measured on days 7, 15 
and 30 in triplicate cultures.
At the specified time periods, cultures were rinsed with PBS (Dulbecco’s Phosphate 
buffered saline, Sigma -  Aldrich Co Ltd, Irvine KA2 8NB,UK) and then fixed in 70% 
ice cold ethanol for a minimum of 1 hour. Cultures were then washed with distilled 
water and stained with 40mM Alizarin Red -  S for 15 minutes followed by 5 further 
washes with distilled water. To remove non specific AR-S stain, cultures were washed 
in PBS for 15 minutes. The AR-S assay was performed by destaining the cell cultures 
by adding 1ml of a solution of 10% (W.V) Cetylpyridium chloride (CPC) in 10 mM 
sodium phosphate, pH 7.0, for 15 minutes at room temperature. AR-S extracts were 
then diluted 10-fold in the 10% CPC solution. lOOpl from each sample was transferred 
to a 96 well plate and absorbance measurements were made at 595nm (reference 
655nm) using a Biorad microplate reader (model 3550, Bio-Rad Laboratories Ltd , 
Hemel Hempstead, Hertfordshire HP27TD ). The concentration of AR-S in each 
sample was calculated using an AR-S standard curve, with the microplate reader 
logistic curve fitting program. The concentration of calcium for each sample was
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determined from the AR-S values. Experiments were performed in triplicate for each
group.
3.3.9. Osteopontin immunoassay
Bone marrow stromal stem cells were seeded onto 6 well plates (10cm ) at a seeding
•  9 •  •  •  •density of 3000 cells per cm . Cells were grown in either control medium or medium 
containing collagen lyophilisate diluted 1:100 or 1:50. Cells were grown for periods of 
14 and 21 days. All medium exchanged during medium changes and collected at 
completion of the growth period was stored at -30° C. Following removal of medium, 
lml of distilled water was placed in each well and the cells were lysed by 2 freeze -  
thaw cycles; 20 minutes at -70° C and 20 minutes at 37° C. The lysate was used to 
determine the DNA content of the cell layer as discussed previously.
Osteopontin expression on days 14 and 21 was determined using a human 
osteopontin enzyme immunometric assay kit (TiterZyme ® EIA., Assay Designs, inc. 
800 Technology Drive Ann Arbour, MI 48108 U.S.A). The optical density of samples 
was measured at 450nm (reference 590nm) with a Biorad microplate reader. A standard 
curve was established using standards comprising human osteopontin in concentrations 
of 640ng/ml, 320ng/ml, 160ng/ml, 80ng/ml, 40ng/ml, 20ng/ml, lOng/ml and 5ng/ml. 
Analysis for calculation of results was performed with the Biorad microplate reader 
logistic curve fitting program.
3.3.10. Type I Procollagen radio immunoassay
Collagen type 1 is released from cells as a procollagen which has a carboxyterminal 
propeptide (PICP). The carboxyterminal propeptide is cleaved extracellularly to leave 
collagen type 1. Measurement of the carboxyterminal pro peptide of collagen type 1 
allows quantification of type 1 collagen synthesis.131,132
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In this study type 1 collagen was quantified using a type 1 procollagen radio 
immunoassay kit (Orion Diagnostica, Orion Corporation. PO Box 83, 02101 Espoo, 
Finland) utilising the radioisotope I 125. A calibration curve was established using 6 
standards comprising procollagen 0, 25, 50, 100, 200 and 500pg/l. The Type I 
Procollagen radio immunoassay was performed in BMSSC cultures grown in control 
medium or medium containing collagen lyophilisate at 7,14 and 21 days.
The assay measures the concentration of the carboxyterminal propeptide of type 1 
collagen. The assay is based on a competitive binding principle. A sample containing 
an unknown amount of procollagen carboxyterminal propeptide is mixed with a known 
quantity of radiolabelled procollagen. The labelled and unlabelled PICP then compete 
with antibody to PICP. When equilibrium is reached, the amount of radiolabelled 
antigen bound to antibody is inversely proportional to the amount of unlabelled PICP.
3.3.11. Statistics
The Kolmogorov -  Smirnov test was used to determine the normality of data. On the 
basis of the Kolmogorov -  Smirnov statistic, it was determined that variable data was 
non-parametric, hence comparisons of cell proliferation, DNA, Alkaline Phosphatase 
activity, osteopontin, collagen type I synthesis were made using the Kruskal Wallis test. 
Comparisons of Calcium content between colloss and control cultures was made using 
the Mann Whitney U test. Data analysis was performed using SPSS for Windows 
version 9.0.0 statistics software (Chicago, IL 60606).
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3.4. Results
3.4.1. Mesenchymal stem cell characterisation using STRO-1 monoclonal 
IgM antibody
Thirty six hours after seeding, bone marrow cells were labelled with Stro-1 monoclonal 
antibody to detect the presence of the STRO-1 cell surface antigen, a stromal stem cell 
marker, (fig.l.)
Fig.l. Enzyme linked immunofluorescence of bone marrow stromal stem cells in 
culture, labelled using anti STRO -1 IgM monoclonal primary antibody, 36 hours after 
seeding and observed with fluorescence microscopy. Magnification x 10.
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3.4.2. Cell morphology
On day 1 of culture, BMSSCs in control and Colloss containing medium showed a 
fibroblastic phenotype typical of bone marrow stromal stem cells. At day 3, the 
majority of cells in the control group maintained a fibroblastic morphology (fig.2a), 
whereas many cells grown in the Colloss containing media developed a polyhedral 
morphology typical of osteoblasts. (figs2b and c). After 5 days in culture with Colloss, 
spindle shaped cells became sparse with the majority of cells showing polyhedral 
morphology typical of osteoblastic differentiation (figs3b and c). These cells appeared 
to account for a higher proportion of cells in the Colloss 1:50 than the Colloss 1:100 
cultures. Control cultures maintained a fibroblastic phenotype (fig.3a).
At day 16 cells in both control and Colloss containing media had reached 
confluence. In contrast to cells in the control group those cultured in Colloss 1:100 and 
1:50 developed multilayered cell aggregates (fig.4 a-c).
Fig.2a. Day 3 BMSSCs in control medium magnification X 10
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Fig.2b. Day 3. BMSSCs cultured in Colloss 1:100 magnification X 10.
Fig.2c.Day 3. BMSSCs cultured in 1:50 Colloss magnification X 10.
Fig.2. Day 3 Photomicrographs of BMSSCs cultured in control medium (a) and 
medium containing Colloss at 1:100 concentration (b) and 1:50 concentration (c). 
Colloss containing media showing the presence of cells with a polyhedral morphology, 
suggesting osteoblastic differentiation.
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Fig.3a. Day 5. BMSSCs cultured in control medium. Magnification X 10
Fig.3b. Day 5. BMSSCs cultured in Colloss 1:100. Magnification X 10.
Fig.3c. Day 5 cultures. BMMSCs cultured in Colloss 1:50. Magnification X 10.
Fig.3 a, b and c. By day 5 BMSSCs in the control group (a) maintain their typical 
fibroblastic appearance whereas some of the cells grown in Colloss 1:100 (b) and most 
cells cultured in the Colloss 1:50 (c) media have developed a polyhedral osteoblastic 
morphology.
Fig.4a. DAY 16. BMSSCs cultured in control media. Magnification X 10
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Fig.4b. Day 16. BMSSCs cultured in Colloss 1:100 media. Magnification X 10.
Fig.4c.Day 16 BMSSCs cultured in Colloss 1:50 media. Magnification X 10.
Fig.4. a, b and c. Day 16. Cells in all culture groups had reached confluence by day 16. 
In contrast to the control cultures (a), the cells grown in Colloss formed complex cell 
aggregations which were more prominent in the Colloss 1:50 (c) than the Colloss 1:100 
group (b).
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3.4.3. Cell Proliferation
Colloss 1:100 and 1:50 vs control media
A comparison of cell proliferation between cells grown in media containing Colloss 
concentration 1:100, 1:50 and cells grown in control media is shown in figure 5. On 
day 1 proliferation rate was greater in Colloss 1:100 cultures than Colloss 1:50 or 
control cultures (p=0.001). BMSSCs cultured in Colloss 1:50 had a higher proliferation 
rate than control cultures (p=0.010).
In all groups there was a significant increase in cell proliferation between days 1 and 
3 (control p=0.04, Colloss 1:100 p=0.002, Colloss 1:50 p=0.004). On day 3, cells 
grown in Colloss 1:50 media had a significantly higher proliferation rate than those 
cultured in control (p=0.001) or Colloss 1:100 media (p=0.001). Cells cultured in 
control media had a higher proliferation than those in Colloss 1:100 media (p=0.001).
At day 9, cells cultured in Colloss 1:100 had a higher proliferation rate than those 
cultured in control or Colloss 1:50 medium (p=0.001) BMSSCs cultured in control 
medium had a higher proliferation than those grown in Colloss 1:50 medium (p=0.001). 
There was a significant decrease in proliferation rate in cells cultured in Colloss 1:50 
and control media between days 3 and 9 (p=0.004), whilst cells cultured in 1:100 
Colloss showed an increase in proliferation rate (p=0.004).
At day 14, in all groups there was a significant fall in proliferation rate between days 
9 and 14 (p=0.004). At this time, cells cultured in Colloss 1:50 had a higher 
proliferation rate than those cultured in control and Colloss 1:100 medium (p=0.001). 
Cells cultured in control medium had a higher proliferation rate than those grown in 
Colloss 1:100 (p=0.001). By day 21, there was no difference in the proliferation rate 
between control and Colloss 1:50 groups. Cells cultured in Colloss 1:50 and control 
medium had a higher proliferation rate than those cultured in Colloss 1:100. (p=0.003).
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Differences in proliferation rate between days 14 and 21 were significant for all groups
(p<0.01).
Bone Marrow Stromal Stem Cell Proliferation Rate
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Fig.5. Graph of proliferation of cells grown in Colloss 1:50 and 1:100 vs control media 
The error bars represent the standard error of the mean
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3.4.4. DNA
At days 1 and 3 there was no significant difference in total DNA between cultures 
grown in control or Colloss containing media. At day 7 Colloss 1:100 cultures had a 
higher DNA content than control and Colloss 1:50 cultures with control cultures 
showing a higher average DNA content than Colloss 1:50 cultures (p=0.027).
In control and Colloss 1:50 cultures there was a significant increase in DNA from 
days 7 to 14 (p=0.050 and 0.046 respectively). DNA in Colloss 1:100 cultures fell 
significantly from day 7 to day 14 (p=0.05). On day 14 there was no significant 
difference in mean DNA between groups.
DNA content in Colloss 1:50 and control cultures increased significantly between 
days 14 and 21. (p=0.05). At day 21 DNA was higher in Colloss 1:50 cultures than in 
Colloss 1:100 or control cultures and control cultures had a higher mean DNA content 
than Colloss 1:100 cultures (p=0.027).
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Fig.6. Boxplot of DNA Content per culture well.
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3.4.5. Osteogenic differentiation of bone marrow stromal stem cells 
cultured in Colloss
3.4.5.1. Staining of mineral with Alizarin red
BMSSC cultures in 35mm six well plates were stained for calcium with Alizarin red on 
days 4, 8, 16 and 21. (fig.7a and 7b.) Calcium was not detected in control cultures or in 
Colloss 1:50 and 1:100 solution without cells. In contrast, Colloss 1:100 and 1:50 
BMSSC cultures showed staining for calcium on day 8. The intensity of stain increased 
to day 21. There was no obvious difference on visual observation of the stain intensity 
between the cultures supplemented with different concentrations of Colloss.
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Fig.7a. Staining of BMSSC cultures for calcium with Alizarin red on days 4, 8 and 16. 
Only the upper three wells in each plate were used for culture
Day 4 Day 8 ^
Control
Colloss 1:100
Colloss 1:50
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Fig.7b. Comparison of day 21 day cultures stained for calcium with Alizarin red. 
Control and Colloss 1:50 cultures
Day 21
Control Colloss 1:50
Figs 7a and b. Control cultures did not stain for calcium at any of the selected time periods 
up to day 21. Alizarin red stained calcium was detected in Colloss supplemented cultures on 
day 8 with the intensity of stain increasing to day 21.
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3.4.5.2. CALCIUM
Calcium content was compared between control cultures and cultures with Colloss 
concentration 1:50. Before day 15, calcium was not detected in control or Colloss 
containing cultures. At day 15 calcium was detected in Colloss containing cultures. The 
calcium content in Colloss cultures increased from day 15 to day 30, but this increase 
was not significant (p=0.513). No calcium was detected in the control cultures for the 
duration of the cultures to day 30 (fig.8). These results indicate that Colloss 1:50 
stimulates an increase in the calcium content of BMSSC cultures.
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Fig.8. Mean calcium content per culture flask. Control vs Colloss 1:50 
The error bars represent the standard error of the mean
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3.4.5.3. Histological Staining of BMSSC Cultures for Alkaline Phosphatase 
Expression.
Alkaline Phosphatase expression by bone marrow stromal stem cells grown in control 
medium and medium containing Colloss on days 4, 8, 16 and 21 is shown in figures 9a- 
e with Alkaline Phosphatase positive cells staining pink.
Alkaline Phosphatase is expressed in the control and Colloss cultures. There 
appeared to be an increase in the number of cells positive for Alkaline Phosphatase in 
both control and Colloss groups as the duration of culture increased.
Fig.9a. Day 4
Control Colloss 1:100
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Fig.9b. Day 8
Control
Colloss 1:50
Colloss 1:100
Fig.9c. Day 12
Control
Fig.9d. Day 16
Control
Colloss 1:50
Colloss 1:100
Colloss 1:100
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Fig. 9e. Day 21
Control Colloss 1:100
3.4.5.4. ALKALINE PHOSPHATASE ACTIVITY (COBAS BIO)
Alkaline Phosphatase expression is shown in fig. 10. On days 7 and 14 there was no 
significant difference in ALP expression between groups. On day 21 Cultures with 
Colloss 1:100 and 1:50 expressed significantly more Alkaline Phosphatase than those 
in control cultures (p=0.027). In all groups Alkaline Phosphatase levels appeared to fall 
from day 7 to 14 but this difference was significant only in the Colloss 1:50 group and 
Colloss 1:100 group (p=0.05). In all groups Alkaline Phosphatase expression increased 
significantly between days 14 and 21 (p=0.05).
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Fig.10. Boxplot of Alkaline phosphatase activity per culture well for 
BMSSC cultures. Control vs Colloss at two different concentrations
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3.4.5.5. OSTEOPONTIN
There was no osteopontin expression on day 14 by BMSSCs cultured in Colloss 1:50. 
There was no significant difference in osteopontin expression between groups on days 
14 and 21 (fig. 11). Osteopontin expression decreased in control and Colloss 1:100 
cultures from days 14 to 21 although this was not significant.
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Fig.ll. Boxplot of Osteopontin expression of BMSSC cultures per culture well.
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3.4.5.6. Procollagen expression
On day 7 there was no significant difference in procollagen synthesis between Colloss 
and control cultures. There was a significant increase in Procollagen synthesis from day 
7 to 14 only in Colloss 1:50 cultures (p=0.050). On day 14, There was no significant 
difference in procollagen between Colloss and control cultures(p=0.113). This 
difference was significant between control and Colloss 1:50 cultures (p=0.05).
On day 21 procollagen expression was highest in Colloss 1:100 cultures although, 
differences in procollagen expression between cultures were not significant. From day 
14 to 21 procollagen increased significantly in control cultures (p=0.05). In control and 
Colloss 1:100 cultures there was a significant increase in procollagen expression 
between days 7 and 21 (p=0.05).
Type 1 Collagen Synthesis
1500-
o>
3
<  1000-
Q
u>
O 500-
CL
I I
DAY7 DAY 14 DAY21
| I control 
|  colloss 1:100  
^  colloss 1 :50
Fig.12. Boxplot of Type 1 collagen synthesis per culture well. 
Measured by quantification of Carboxyterminal pro-peptide.
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3.5. Discussion
The findings of this study give some support to the hypothesis that Colloss stimulates 
the osteoblastic differentiation of bone marrow stromal stem cells in vitro. Some, but 
not all, of the markers of osteogenic differentiation were enhanced by the addition of 
Colloss to culture medium. The addition of Colloss to culture medium resulted in 
increased Alkaline Phosphatase expression, increased collagen type I expression and 
changes in cell morphology. Perhaps the most significant finding was that of calcium 
deposition in the Colloss containing cultures.
Bone marrow stromal stem cells express a multitude of cell surface markers which 
include integrins, growth factor and cytokine receptors, cell adhesion molecules and
1 1 o
several miscellaneous antigens. Many of these markers are also expressed by 
differentiated mesenchymal tissue cells such as adipocytes, fibroblasts, chondrocytes 
and osteoblasts.133
Attempts have been made to isolate cell surface markers specific for bone marrow 
stem cells. Although several markers including SH2, SH3 and STRO-1 have been 
proposed as specific stromal stem cell markers, there remains debate about their 
validity.133'134'135 136’137
In this study we used STRO-1 as a marker for bone marrow stromal stem cells. It has 
been identified on the surface of primitive stromal stem cells. The multipotential nature 
of STRO-1 positive bone marrow cells was demonstrated by Simmons et al 1991.124 In 
this study human BMSSCs positive for STRO-1 were grown in long term culture. 
These cultures generated several stromal cell types which included adipocytes, smooth 
muscle cells and fibroblasts .124
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In a further study Dennis et al 2002 demonstrated the multipotential properties of 
STRO-1 positive bone marrow cells by stimulating their differentiation into osteoblasts, 
chondrocytes, adipocytes and fibroblasts.123 Although these studies provided evidence 
that STRO-1 positive cells can differentiate to form a variety of mesenchymal cell 
types, they have not demonstrated the multipotential ability of individual STRO-1 
positive cells. This would require the stimulation of cloned STRO-1 cells to 
differentiate along the various lineage pathways.
Support for the validity of the STRO - 1 positive cells used in this study comes from 
the fact that another investigator in our institution stimulated differentiation of these 
cells into osteoblasts and adipocytes by adding osteogenic and adipogenic supplements 
to culture media.
The patterns of proliferation rate were similar in all cultures, with an early rapid 
proliferation phase to day 3 in Colloss 1:50 and control cultures and to day 9 in Colloss 
1:100 cultures. This is followed by a rapid fall in proliferation rate from day 9 to 14 in 
all groups. Between days 14 and 21 there was a further decline in cell proliferation 
activity except for the Colloss 1:100 group where there was a moderate increase in cell 
proliferation.
As early as day 3, cells cultured in Colloss containing media, developed a polygonal 
phenotype typical of osteoblastic differentiation. At day 5 the majority of cells 
appeared to demonstrate this appearance. In contrast, cells grown in control media 
maintained spindle type morphology until confluence at day 16.
On subjective observation, there appeared to be a larger proportion of cells visualised 
under light microscopy with a polygonal appearance in the 1:50 Colloss group 
compared to the 1:100 Colloss group at day 5. However, confirmation would require 
more objective methods of quantification to determine whether increasing the 
concentration from 1:100 to 1:50 had a stimulatory effect on the differentiation of
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human bone marrow stromal stems to express an osteoblastic phenotype. At day 16 
cultures in control and Colloss containing media had reached confluence. Cells in the 
Colloss groups developed a complex multilayered configuration, which was not seen in 
control cultures.
The early phenotypic changes of bone marrow cells cultured in Colloss medium 
observed in this study are similar to those described by Jaiswai et al 1997,78 who 
developed a culture system to examine the effect of osteogenic supplements on bone 
marrow stromal cells. When the osteogenic supplements dexamethasone, sodium p 
glycerophosphate and ascorbic acid were added to culture medium, BMSSCs were 
shown to develop an osteoblastic morphology as early as day 2, with cells later forming
7ftmultilayered configurations.
The ability of Colloss to stimulate the differentiation of bone marrow stromal stem 
cells along osteoblastic lineage pathways is further supported by the higher Alkaline 
Phosphatase activity levels found in the Colloss containing cultures on day 21. There 
was a stepwise increase in culture DNA content from day 1 through to peak levels on 
day 21 in the control and Colloss 1:50 cultures. In the Colloss 1:100 cultures, peak 
DNA content was measured on day 7.
Alkaline Phosphatase has a role in the mineralisation process during osteogenesis. In 
vivo it hydrolyses organic phosphates in the extracellular matrix, resulting in the 
release of phosphate which precipitates with calcium to form mineral apatite. Previous 
studies have examined Alkaline Phosphatase activity in bone marrow stromal cell 
cultures grown in osteogenic media. Majors et al, 1997, cultured human bone marrow 
stromal cells in media containing the osteogenic supplements (3 glycerophosphate 
sodium ascorbate and dexamethasone.138 Alkaline Phosphatase was measured using a 
nitrophenyl phosphate ALP assay. Osteoblastic differentiation and mineralisation of
68
cultures was associated with Alkaline Phosphatase levels which increased between 
days 9 and 16 then remained relatively constant to day 30.
Jaiswal et al, 1997, examined the effects of osteogenic supplements on BMSSCs in
7 R •vitro. BMSSCs showed an increase in Alkaline Phosphatase activity to day 12 in both 
the control and osteogenic supplemented cultures. Cultures with osteogenic 
supplements had a higher ALP activity than the control cultures on days 4, 8, 12 and 
16. ALP activity in the osteogenic supplemented stem cells peaked at day 12 then 
declined to day 4 levels on day 16.
In my study alkaline phosphase activity increased significantly from days 14 to 21 in 
both the control and Colloss cultures, and on day 21 was greater in the Colloss cultures 
than control cultures. Surprisingly there was no statistical difference in Alkaline 
Phosphatase activity between day 7 and day 21 in any of the groups.
The ability of Colloss to stimulate the mineralisation of stromal stem cell cultures 
provides further confirmation of its osteogenic capacity. There was evidence of matrix 
mineralisation at 8 days in Colloss cultures, whereas no calcium was detected in control 
cultures for the 30 day culture duration. The lack of mineralisation of stromal stem cell 
cultures in the absence of osteogenic supplements or growth factors has been shown in 
previous studies78. Mineralisation induced by Colloss occurred earlier than has been 
reported in studies where BMSSCs have been cultured with osteogenic supplements,
on
when evidence of mineralisation can take up to 5 weeks. However, the onset of 
mineralisation has varied between studies and Majors et al, 1997, reported matrix 
mineralisation at 17 days using Alizarin red to stain for calcium in cultures of bone 
marrow cell aspirates and Bruder et al 1998 observed mineralisation of matrix at 16 
days using von kossa histochemistry to stain for calcium in BMSSCs cultured in
13R 118osteoinductive supplemented media. ’
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Osteopontin is an extracellular protein expressed by osteoblasts which is involved in
1Wcell attachment during the process of bone formation and remodelling. It has been 
shown to accumulate in the mineralised matrix of new bone.140 More recently the 
expression of osteopontin by osteoclasts has been demonstrated.141 There is evidence 
that osteopontin can enhance osteoclast motility and ability to resorb bone.142 Despite 
its expression by osteoclasts143, it has been used as a marker of osteogenesis in several 
studies 144,145,146. Bruder et al, 1998, examined the expression of osteopontin mRNA in
i 1 a
a bone marrow stromal cell culture system. It was expressed maximally in the late 
phase of osteogenesis.
At the 14 and 21 day time points chosen to measure oseopontin, no difference was 
noted between control and Colloss containing cultures. It is possible that day 21 was 
too early in the osteogenic process, and that longer culture periods are required before 
maximal expression of osteopontin occurs. We found that osteopontin was expressed in 
the control BMSSCs untreated with Colloss. This has been demonstrated in previous 
studies where BMSSCs have been cultured in vitro in the absence of osteogenic 
supplements.118,147 Although osteopontin is expressed by osteoblasts, its presence does 
not signify mineralisation. It is a fairly non specific marker of osteogenesis and its 
expression in the absence of mineralisation has been described.148,149 Therefore, 
although the expression of osteopontin was not enhanced by Colloss, one cannot 
conclude that Colloss does not enhance osteogenesis.
Summary
Some, but not all, of the osteogenic markers measured in this study provided evidence 
suggesting that Colloss enhances the osteogenic differentiation of bone marrow stromal 
stem cells. Perhaps the most significant finding was the deposition of calcium in the 
Colloss treated specimens from day 15 onwards. Further evidence comes from the 
morphological changes noted in the Colloss treated specimens at an early stage.
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4. Chapter 2
An Investigation of Growth and Differentiation of Bone Marrow 
Stromal Stem Cells Cultured on Smooth Polished Titanium 
Pre - Treated with Colloss
4.1. Introduction
Titanium is a biomaterial which is frequently used for the manufacture of orthopaedic
OQ O fi 1 Aprosthetic implants. ’ ’ Titanium alloy has favourable characteristics which include 
its biocompatibility, corrosion resistance, light weight and the ease with which it can be 
machined by implant manufacturers.
Loosening of the femoral prosthesis remains a major factor limiting the longevity of 
total hip replacements. The loosening process is multi-factorial and is influenced by 
implant design, surgical technique and patient dependent variables. An important 
mechanism of the loosening process in total hip replacements is the formation of 
polyethylene wear particles from the acetabular component, which migrate along the 
interface between bone and implant and cement-bone interfaces. On reaching these 
interfaces they are phagocytosed by macrophages. This stimulates macrophages to 
release cytokines, resulting in the activation of osteoclasts, leading ultimately to 
periprosthetic bone resorption.150 Eventually a fibrous membrane forms at the bone 
implant interface.151 This fibrous layer compromises biological bonding between the 
femoral stem and host bone, leading to an increase in motion between the implant and 
host, thus exacerbating the loosening process.
Current methods of improving the osseointegration of femoral stems include: the 
provision of flutes to improve the initial anchorage of un-cemented femoral stems to 
host bone; modification of surface topography of the implant by shot blasting and
| f a | f ^ -i » i | »»
porous coating with titanium or hydroxyapatite (HA). ’ ’ ’ Hydroxyapatite has
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been shown to be effective in enhancing the osseointegration of coated femoral stems.
It has osteoconductive properties, enhancing the ingrowth of osseous tissue at the 
implant surface, but its osteoinductive capacity is limited. Furthermore, in the longer 
term, HA coatings are susceptible to delamination and degradation. 64,157,158
Cell interactions at the implant -  host interface are important and govern the 
osseointegration process. The osseointegration process involves the formation of bone 
from the endosteal surface of the medullary cavity which grows towards the 
implant.61,159 Bone deposition may also occur at the implant surface following the 
deposition of a bone like apatite layer.160,161
Bone marrow stromal cells are primitive cells which have the ability to differentiate 
along lineage pathways to form bone, fibrous tissue and adipose tissue. They are 
present within the medullary cavity and are involved in the process of new bone 
formation on cemented implants. The growth, attachment and differentiation 
characteristics of bone marrow stromal cells on titanium surfaces has been investigated 
in previous studies. Titanium surface characteristics have been shown to influence cell 
adhesion, proliferation and differentiation. Deligianni et al 2001 found that increasing 
the roughness of titanium surfaces resulted in an increase in human BMSSC adhesion 
and proliferation.162 With regards to differentiation of BMSSCs along osteogenic 
pathways, Ter Brugge et al, 2002 , found that osteocalcin was expressed to a greater 
degree on smooth rather than rough surfaced titanium, but Castellani et al, 1999, was 
unable to demonstrate any effect of surface roughness on cell differentiation.164
Surface treatment of titanium by various methods has been shown to influence 
cellular morphology, proliferation and differentiation. Such treatments include 
topographical modification, calcium phosphate coating, alkali and heat treatment. 52, 
165,166,167 Titanium forms an oxide layer on exposure to air, which provides the excellent 
corrosion resistive properties of titanium alloys. If this layer is compromised, there will
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be an increase in the release of metal ions. There is evidence to suggest that metal ion 
release can influence osteoblast behaviour. Ching-Hsin et al, 2002, examined 
proliferation and ALP activity from osteoblasts grown on titanium which had 
undergone ageing treatment to reduce metal ion release and non-treated titanium.168 
Osteoblasts grown on treated titanium demonstrated a higher proliferation rate at 72 hrs 
and expressed a peak ALP level later than the control group.
The coating of implants with substances which have osteoinductive properties may 
provide a means of utilising the bone regenerative capacity of BMSSCs within the 
medullary cavity of the femur to improve osseointegration of femoral stem prostheses. 
The differentiation of such cells along osteogenic lineage pathways and the formation 
of mineral apatite on implant surfaces provide a mineralisation front, stimulating new 
bone formation which may improve osseointegration of metallic implants.
Colloss has osteoinductive properties. It contains cytokines which have stimulatory 
effects at several intermediate stages in the cascade of osteogenesis. This study will 
investigate the ability of Colloss to stimulate proliferation and osteogenic 
differentiation of bone marrow stromal stem cells growing on titanium biomaterials.
4.2. Aim and Hypothesis
Aim - To investigate the the effect of Colloss on the proliferation and differentiation of 
BMSSCs cultured on titanium biomaterials
Hypothesis -  Colloss will enhance the osteogenic differentiation of bone marrow 
stromal stem cells cultured on smooth polished titanium
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4.3. Materials and Methods
4.3.1. Preparation of Titanium Implants
Titanium alloy disks (Titanium318 TiV4AL6, Titanium International Ltd. Keys House 
Granby Ave, Birmingham B33 OSP, England) of diameter 5mm were “smooth 
polished” using silica alumina paste (Buehler alpha micro polish 1 Alumina, 41 
Waukegan Rd. Lake Bluff. IL60044 USA). They were then immersed transiently in 
70% alcohol followed by rinsing with distilled water. Disks were autoclaved at 126 
degrees centigrade (11 minute sterilising time) using a Prestige Medical, series 2100, 
clinical autoclave. (P.O. Box 154 Clarendon Road, Blackburn, 
Lancs, BB1 9UG. UK).
4.3.2. Application of Colloss to Titanium Implants
Titanium disks were placed in the wells of a 24 well tissue culture plate. Colloss coated 
disks were prepared by pipetting 50 pi of collagen lyophilisate suspension (Colloss 
dispersion, concentration 1.4d.m./ml, Ossacur AG, Oberstenfeld, Germany) on to the 
surface of each titanium disk in the experimental group. In the control group titanium 
disks were also placed in 24 well culture plates but were not coated with Colloss 
suspension. Disks were then left undisturbed for a period of one hour prior to the 
seeding of bone marrow stromal stem cells.
4.3.3. Seeding of Titanium Disks with Bone Marrow Stromal Stem Cells
Bone marrow stromal stem cells were isolated and cultured as described in Chapter 
1(3.3.1). Each titanium disk was placed in the well of a 24 well culture plate. Thirty 
thousand (3xl04) cells were seeded onto each smooth polished titanium disk using a 
micro pipette. After seeding of bone marrow stromal stem cells, the 24 well plates 
containing titanium disks were incubated at 37°C in 95% air and 5% carbon dioxide at
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100% humidity. After 30 minutes of incubation, 2 mis of standard medium comprising 
Dulbecco’s modified Eagles medium (4500mg/L glucose/L, L-glutamine and sodium 
pyruvate, Sigma Aldrich D6429), with 1% Penicillin / Streptomycin. (Sigma-Aldrich 
Co Ltd, Irvine UK) and 10% bovine foetal calf serum (FCS) was added to each well 
containing titanium disks. One day after cell seeding, the medium was discarded and 
titanium disks were transferred to another 24 well tissue culture plate (Day 0). This was 
performed to exclude cells which may have migrated onto the tissue culture plastic of 
the 24 well plate after seeding. Medium changes were performed at selected intervals, 
at the same time for the control and Colloss coated titanium disks.
4.3.4. Cell Proliferation Using Alamar™ Blue Assay
The alamar blue assay provides a means of quantifying cell proliferation. It contains a 
REDOX indicator that fluoresces and changes colour in response to cellular 
proliferation. Colour change can then be quantified by measuring absorbance.
Cell proliferation was measured on days 1, 3, 9, 14 and 21 using an alamar blue 
assay, utilising techniques described in chapter 1 (3.3.5). At the selected time intervals 
medium was removed from culture wells and replaced with 2mls of a solution 
containing Alamar blue 1:10 in standard medium. Cells were then incubated for 4 hours 
at 37° C, humidity 100%, 5% CO2. After the four hour incubation period, two 100 pi 
aliquots of medium were then removed from each well and transferred to a 96 well 
plate.
Absorbance was measured at 595nm with a reference wavelength of 655nm using a 
Biorad microplate reader (model 3550, Bio-Rad Laboratories Ltd , Hemel Hempstead, 
Hertfordshire HP2 7TD ). Analysis was performed in triplicate cultures. Culture of
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cells was continued by removing the remaining alamar blue containing medium from 
the wells and replacing it with standard medium.
4.3.5. Total DNA Measurement
Total DNA was measured on days 7, 14 and 21 using the fluorometric DNA binding 
dye, Hoescht 33258, as described in chapter 1 (3.3.6.). At selected time intervals 
medium was removed from the culture plate wells containing the titanium disks and 
replaced with 1ml of distilled water. Lysis of cells to release DNA was performed by 2 
freeze thaw cycles, freezing cells to -70° C for 20 minutes followed by warming to 37° 
C for 20 minutes. DNA from calf thymus was used for the preparation of a standard 
curve, as described in chapter 1 (3.3.6.2).
One hundred microlitres of cell lysate and DNA standard was transferred to a 96 
well plate in duplicate (Falcon™, Becton, Dickinson, NJ, USA). One hundred 
microlitres of Hoechst 33258 diluted to 1 pl/ml of saline sodium citrate buffer was also 
added to each well. Fluorescence was measured at 460nm using a flurometer (Ascent 
reader, Labsystems Inc, 8 East Forge Parkway, Frankin, MA 02038, USA). Analysis 
was performed using Genesis software package.
4.3.6. Alkaline Phosphatase assay
Alkaline Phosphatase was measured on days 7, 14 and 21 using the technique 
previously described in chapter 1 (3.3.7.). Culture medium was removed from wells of 
the 24 well plate and replaced with 2mls of distilled water. Cells were lysed to release 
ALP with a freeze thaw cycle of freezing to -70° C for 20 minutes followed by 37° C 
for 20 minutes, which was performed twice. A 50pl sample of distilled water was taken 
from each well, from which ALP activity was analysed using the Cobas Bio analyser.
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4.3.7. Type I Procollagen carboxyterminal propeptide radio immunoassay
Radioimmunoassay of the carboxyterminal propeptide of type 1 procollagen was used 
as a measure of type 1 collagen synthesis using the techniques described in chapter 1 
(3.3.10). Type one collagen synthesis was measured from the culture medium in which 
the control and Colloss coated titanium disks were grown. All medium collected during 
medium changes and at completion of the growth period was stored at -30°.
Type I Procollagen in control titanium and Colloss treated titanium bone marrow 
stromal cell cultures was measured in culture medium on days 14 and 21 using a type 1 
procollagen radioimmunoassay utilising the radioisotope 1 125(Orion Diagnostica, Orion 
Corporation. PO Box 83, 02101 Espoo, Finland). A calibration curve was established 
using 6 standards comprising procollagen 0,25, 50,100,200 and 500pg/l.
4.3.8. Osteopontin immunoassay
Osteopontin was measured from the culture medium in which the control and Colloss 
coated titanium disks were grown using the technique described in chapter 1 (3.3.9.). 
All medium exchanged during medium changes and collected at completion of the 
growth period was stored at -30° C. Osteopontin expression on days 14 and 21 was 
determined using a human osteopontin enzyme immunometric assay kit (TiterZyme ® 
EIA., Assay Designs, Inc. 800 Technology Drive Ann Arbour, MI 48108 U.S.A).
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4.3.9. Scanning Electron Microscopy
Titanium and bone marrow stromal stem cell culture samples were prepared for 
electron microscopy at selected time intervals. Disks were fixed in 1.5% glutaraldehyde 
and 0.1 M sodium cacodylate buffer for 48 hours at 4 degrees. Samples were then 
washed in 0.2% sodium cacodylate for 1 hour and fixed in Osmium tetroxide 1% in 0.1 
M sodium cacodylate buffer. Samples were then washed twice for 5 minutes in 0.2M 
sodium cacodylate and placed in 1% tannic acid in 0.05% sodium cacodylate for 1 
hour. Samples were then washed with sodium cacodylate buffer 4 times (2 minutes 
each) and dehydrated in increasing concentrations of alcohol before air drying in 
hexamethyl disalazane. Samples were mounted onto electron microscopy stubs. Silver 
in methyl isobutyl ketone (Acheson electrodag 1415M) was applied to the sample -  
stub interface to prevent charging by the electron beam. Samples were then coated with 
Palladium using an Emitech K550 coating apparatus. Microscopy was performed using 
a JEOL (JSM-550LV) scanning electron microscope.
4.3.10. Statistics
On the basis of the Kolmogorov -  Smirnov statistic it was determined that variable data 
was not normally distributed. Statistical comparison between treated and control 
samples for cell proliferation, DNA, Alkaline Phosphatase, osteopontin and collagen 
type I synthesis comparisons were made using the Mann Whitney U test.
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4.4. R esults
4.4.1. Cell proliferation rate
In both groups, proliferation rate increased significantly between days 1 and 3 (fig.l.) 
(p=0.004), at which time proliferation peaked in both groups. There was no statistical 
difference in peak proliferation rate between groups on day 3. From day 3 to day 9 
proliferation rate decreased significantly in control cultures (p=0.004). Day 9 
proliferation rate was significantly greater on cells grown on titanium pre-treated with 
Colloss than those in the control group (p=0.016). From days 9 to 14 proliferation rate 
decreased significantly (p=0.004) in the pre-treated titanium group and by day 14 
proliferation was significantly lower than cells in the control group (p=0.010). From 
day 14 to 21 cell proliferation rate fell significantly in both Colloss and control groups 
(p=0.004).
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4.4.2. Total DNA
There was no significant difference in total DNA in control and Colloss cultures on 
days 7, 14 and 21(fig.2.).
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Fig.2. Boxplot of BMSSC DNA per culture well.
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4.4.3. Alkaline P hosphatase  Activity
On day 7 Alkaline Phosphatase activity was greater in the Colloss group than control 
cultures (p=0.050) (fig 3.). On day 14 there was no difference in ALP expression 
between control and Colloss cultures and on day 21 ALP activity in control cultures 
was greater than in the Colloss group (p=0.050). Alkaline Phosphatase activity did not 
differ significantly between days 7, 14 and 21 in control cultures. From days 7 to 14 
Alkaline Phosphatase activity decreased significantly in the Colloss group (p=0.05).
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Fig.3. Boxplot of Alkaline phosphate activity per well.
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4.4.4. Procollagen Expression
There was no difference in procollagen measured between cells grown on titanium 
treated with Colloss and BMSSCs grown on non-treated titanium on days 14 and 21 
(fig.4). Procollagen expression increased significantly from days 14 to 21 only in 
control cultures (p=0.050).
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4.4.5. O steopontin expression
Osteopontin expression increased significantly from days 14 to 21 in the group pre 
treated with Colloss (P=0.05). On days 14 and 21 osteopontin expression was 
significantly greater in the group pre-treated with Colloss than the control group. There 
was no significant difference in osteopontin expression between control cultures on 
days 14 and 21 (fig.5.).
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Fig.5. Boxplot of Osteopontin Expression per culture well.
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4.4.6. Scanning Electron Microscopy
Scanning electron microscopy was performed to determine the morphology of cells 
cultured on the titanium biomaterials. BMSSC morphology in control and Colloss 
groups is shown in figs 6, 7 and 8.
Fig.6a and b. Day 7. BMSCCs S.E.M. X 600.
b
Fig.6. Control cells (a) and cells cultured on titanium pre treated with Colloss (b).
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Fig.7a and b. Day 14. BMSSCs. SEM x 200. (A) control; (B) Colloss
b
Day 14. Both control (a) and Colloss (b) treated groups have reached confluence. Cells 
on Colloss treated titanium (b) appear to have a more random orientation compared to 
the control group.
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Figs.8a and b. BMSSCs. Day 21. S.E.M. magnification X 600.
b
Fig.8. Cells at day 21 showing confluence of cells grown on both control (a), and 
Colloss (b) pre-treated titanium. Cell morphology is similar in both groups.
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4.5. Discussion
A prerequisite for the stability and longevity of uncemented orthopaedic implants is 
periprosthetic bone formation and implant osseointegration. The osseointegration of 
orthopaedic implants relies on the formation of bone directly onto prosthetic surfaces. 
In the case of uncemented femoral hip replacement stems implanted within the femoral 
canal, there are bone marrow stromal stem cells in close proximity to the prosthesis 
which have the ability to differentiate into osteoblasts,which in turn can form bone. A 
greater understanding of the interactions between bone marrow stromal stem cells and 
orthopaedic biomaterials may facilitate the development of techniques to enhance 
periprosthetic bone formation and osseointegration. Previous studies have examined the 
effects of different biomaterials on the growth and differentiation of bone marrow 
stromal stem cells. Ohgushi et al 1996 169 examined the behaviour of rat marrow 
stromal stem cells on bioactive glass ceramics with and without an apatite layer. It was 
shown that osteoblastic differentiation was enhanced by the presence of the apatite 
layer as evidenced by increased levels of Alkaline Phosphatase, mineral deposition and 
bone specific GLA protein. 169
Other studies have examined the growth of mature osteblasts on titanium and the 
effects of surface treatments on cell behaviour. Ching-Hsin Ku et al, 2002, 
demonstrated that aging titanium alloy to reduce metal ion release had the result of
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increasing significantly the proliferation of osteoblasts. However, few studies have 
examined the growth and differentiation characteristics of multipotential bone marrow 
stromal stem cells cultured on titanium alloy. In this chapter we have demonstrated the 
ability of bone marrow stromal stem cells to attach and proliferate on titanium alloy, a 
material in common use for the manufacture of hip replacement femoral components. 
The ability of Colloss treated titanium to enhance the osteoblastic differentiation of
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bone marrow stromal stem cells is supported by the increased levels of Alkaline 
Phosphatase at day 7 and the increased osteopontin levels at days 14 and 21. Levels of 
Alkaline Phosphatase and osteopontin were several magnitudes greater than control 
samples. In control cultures ALP expression remained low and did not change 
significantly between days 7, 14 and 21. In contrast, the experimental groups showed a 
peak in ALP expression at day 7, which was followed by a sharp fall in ALP activity to 
day 14.
Osteopontin is a glycosylated phosphoprotein with a molecular weight of 32,600 
which is expressed by osteoblasts and may be involved in cellular attachment. It binds 
to calcium and interacts with the CD44 cell surface glycoprotein which can attach to 
collagen type I, fibronectin and hyaluronic acid.170,171 There is evidence that it is 
involved in the process of osteoclastosis and remodelling.143,172 During the cascade of 
osteogenesis, peak bone formation only usually occurs after Alkaline Phosphatase 
expression in the latter stages of osteogenesis.118 In control cultures, Ostepontin 
expression was minimal and did not vary significantly during the study period. In the 
Colloss groups, osteopontin expression was three times that of the control cultures on 
day 14 and more than 10 times the mean day 21 control value. This would suggest that 
Colloss is stimulating the osteogenic differentiation of bone marrow stromal stem cells 
on the titanium surfaces. Surprisingly, there was no difference in the rate of type I 
collagen synthesis between control and Colloss cultures.
Evidence of a stimulatory effect of Colloss on the osteoblastic differentiation of 
BMSSCs comes from increased early Alkaline Phosphatase expression and raised 
osteopontin levels. It is possible that when medium was initially added to the titanium 
disks, Colloss may have been washed off the titanium surface. This would result in a 
1:40 dilution of Colloss suspension within the medium. On subsequent exchange for 
fresh medium, Colloss would be removed from culture. This may explain why
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enhancement of Alkaline Phosphatase activity was confined to the early culture period. 
However, procollagen expression was not significantly influenced in the Colloss pre­
treated titanium samples and morphological appearances were non- specific.
The effect of bone morphogenic protein on the proliferation and differentiation of 
bone marrow stromal stem cells grown on titanium has been investigated previously. 
Van Den Dolder et al cultured rat bone marrow stromal cells on machined titanium 
with and without the addition of BMP2. Unlike this study, BMP 2 was added to culture
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medium. In contrast to our results, BMP 2 did not have an effect on cell 
proliferation, however, the time points used were 4, 8 and 16 days which differed from 
this study. BMP 2 appeared to induce the osteogenic differentiation of stromal stem 
cells resulting in the early expression of Alkaline Phosphatase, calcium deposition and 
matrix formation.
Summary
The results of this study provide evidence in support of the osteogenic 
potential of Colloss to stimulate the differentiation of bone marrow stromal stem cells 
along osteoblastic lineage pathways. Evidence, however, is inconclusive because 
collagen type 1, a marker of osteogenesis was not elevated in the Colloss treated 
titanium samples.
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5.Chapter 3
Proliferation and Differentiation of Bone Marrow Stromal Stem 
Cells on Hydroxyapatite Granules Treated with Colloss
5.1. Introduction
Hydroxyapatite (Caio (P04)6 (OHfe) has a composition similar to that of bone. Its 
biocompatible and bioactive properties have favoured its use as a bone graft substitute
1 'fyf 1 |  I C C
material and as a coating to enhance osseointegration on implants. ’ Its
bioactivity is characterised by its ability to ellicit a biological reaction at its surface 
which results in chemical bonding to bone.176
When hydroxyapatite (HA) is exposed to tissue fluids, a hydroxylcarbonate apatite 
layer forms which resembles the mineral phase of bone and provides a bioactive 
interface for new bone formation, resulting in bonding with bone.177, 178,179’ 180 When 
bonding is established, collagen fibres may interdigitate with the hydroxyapatite 
crystals near the interface. Such chemical bonding is strong and the interface shear 
strength may exceed the cohesive strength of hydroxyapatite to attached prosthesis.
It has been established that Hydroxyapatite is osteoconductive, hence supports the 
proliferation, migration and differentiation of osteoprogenitors, but there remains 
controversy as to whether it is has any osteoinductive properties.26,59,60, 176
The general consensus is that hydroxyapatite is not greatly osteoinductive, but 
hydroxyapatite implanted in extraskeletal sites in animals and humans has been shown 
to support new bone formation.181, 182, 183 Some authors consider this evidence of 
osteoinductive capacity, but others attribute this apparent osteoinduction to binding of
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endogenous bone morphogenic proteins onto the hydroxyapatite surface. ’ ’
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When applied to the surface of orthopaedic implants, such as femoral stems of total hip 
replacements, hydroxyapatite facilitates bone ingrowth onto implant surfaces. 456 The 
close apposition of bone to prosthetic joints is desirable to enhance implant stability, 
reduce the risk of loosening and improve implant longevity.
There is an abundance of osteoblasts within the bone marrow which can produce 
bone matrix onto the hydroxyapatite surface. In addition, multipotential bone marrow 
stromal stem cells within the medullary cavity provide a potential source of 
osteoprogenitors to facilitate new bone formation during the process of implant 
osseointegration.
The excellent osteoconductivity of HA confers an ability to support the growth, 
proliferation and migration of osteoprogenitors and osteoblasts during the process of
77 SO 1RSosseointegration. ’ ’ Hydroxyapatite’s low osteoinductive capacity could be 
overcome by combining it with an osteoinductive substance to form a composite 
biomaterial. HA can absorb liquids, hence can be used as a carrier for soluble factors. 
These properties make HA ideal as a carrier for Colloss suspension.
5.2. Aim and Hypothesis
Aim - The aim of this chapter is to examine and compare the growth and differentiation 
of human bone marrow stromal stem cells cultured on hydroxyapatite and 
hydroxyapatite pre-soaked with a Colloss suspension
Hypothesis — Colloss will enhance the osteogenic differentiation of bone marrow 
stromal stem cells cultured on the surface of hydroxyapatite.
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5.3. Materials and methods
5.3.1. Bone marrow stromal stem cell harvest and culture.
Using methods described in chapter 1 (3.3.1), human bone marrow stromal stem cells 
were harvested from the iliac crest of an adult female volunteer undergoing an elective 
orthopaedic procedure. Bone marrow stromal stem cells were isolated from marrow 
using a Ficoll gradient technique, seeded onto culture flasks and incubated in 
monolayer, at 37°C in 95% air and 5% carbon dioxide at 100% humidity. The standard 
medium used for culture comprised Dulbecco’s modified Eagles medium (4500mg/L 
glucose/L, L-glutamine and sodium pyruvate, Sigma Aldrich D6429), with 1% 
penicillin / streptomycin. (Sigma-Aldrich Co Ltd, Irvine UK) and 10% bovine foetal 
calf serum (FCS).
5.3.2. Hydroxyapatite preparation and seeding with BMSSCs
Granules of coarse pore foam Hydroxyapatite, particle size 4-8mm were used in this 
study (Plasma Biotal Limited Whitecross Road Industrial Estate, Tideswell, SKI 7 
8PY). Four granules of hydroxyapatite were placed in individual wells of a 24 well 
culture plate.
In order to minimise variations in hydroxyapatite surface area between control and 
Colloss cultures, granules were visually inspected and those which appeared identical 
in size were selected. Such inspection is subjective and Is unlikely to eliminate 
differences in surface area, but the aim was to reduce such variation to a minimum. To 
further standardise the surface area of Hydroxyapatite the same number of granules 
were placed in each culture well.
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Pre-treatment of granules with Colloss was performed by pipetting Colloss suspension 
(Colloss dispersion, concentration 1.4d.m./ml, Ossacur AG, Oberstenfeld, Germany) to 
cover the surface of hydroxyapatite granules. Granules were then left to stand at room 
temperature for 1 hour. Granules were then transferred to another 24 well plate to 
exclude Colloss which may have spread onto the base of the wells. The control cultures 
comprised Hydroxyapatite granules alone without Colloss pre-treatment.
Bone marrow stromal stem cells were seeded onto the hydroxyapatite granules by 
pipetting medium containing bone marrow stromal stem cells at a density of 800,000 
cells/ml onto the surface of hydroxyapatite granules. After seeding, the granules were 
incubated for 30 minutes to allow the cells to attach to the HA prior to adding 2mls of 
standard medium to each well. Cell proliferation, total DNA, Osteopontin and 
procollagen were measured in triplicate cultures. After 24 hours the granules were 
transferred to a new 24 well culture plate to exclude bone marrow stromal stem cells 
which may have been present on the bottom of the culture wells.
5.3.3. Cell proliferation assay using alamar™ blue Assay
Cell proliferation was measured using an alamar blue assay, utilising techniques 
described in chapter 1 (3.3.5.) on days 7,14 and 21 of culture.
5.3.4. Total DNA using Hoescht 33258
Total DNA was measured on days 7, 14 and 21 using the fluorometric DNA binding 
dye, Hoescht 33258 as described in chapter 1 (3.3.6.).
5.3.5. Alkaline Phosphatase assay on Cobas Bio analyser
Alkaline Phosphatase was measured on days 7, 14 and 21 using a technique adapted 
from Oreffo et al 1998 119 which is described in chapter 1(3.3.7.).
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5.3.6. Type I Procollagen radio immunoassay
Type 1 collagen synthesis was measured on days 7, 14 and 21 of culture with a type I 
procollagen radioimmunoassay (Orion Diagnostica, Orion Corporation. PO Box 83, 
02101 Espoo, Finland) using the techniques described in chapter 1(3.3.10.).
5.3.7. Osteopontin immunoassay
Osteopontin was measured on days 14 and 21 using a human osteopontin enzyme 
immunometric assay kit (TiterZyme ® EIA. Assay Designs, Inc. 800 Technology Drive 
Ann Arbour, MI 48108 U.S. A). The technique has previously been described in chapter 
1(3.3.9.).
5.3.8.Scanning Electron Microscopy
Samples of stem cell - Hydroxyapatite composites were prepared for electron 
microscopy after selected periods of culture. The methods of sample processing is 
described in chapter 2 (4.3.9). Microscopy was performed using a JEOL model JSM- 
550LV Scanning Electron Microscope.
5.3.9. Statistics
On the basis of the Kolmogorov -  Smirnov statistic it was determined that variable data 
was non parametric. Statistical analysis of variables was therefore performed using the 
Mann Whitney U-test.
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5.4. RESULTS
5.4.1. Cell proliferation.
There was no significant increase in cell proliferation rate between control and Colloss 
groups on days 1, 3, 9 and 14. On day 21 control cultures had a higher proliferation rate 
than Colloss cultures (p=0.004). In both groups cell proliferation Increased significantly 
from days 1 to 3 (p=0.004). From days 3 to 9 cell proliferation in the Colloss group 
decreased significantly (p=0.016), whereas cell proliferation rate in control cultures did 
not change significantly. From days 9 to 14 cell proliferation fell significantly and 
increased significantly between days 14 and 21 (p=0.004). In both groups proliferation 
rate peaked on day 21 (Fig. 1.).
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5.4.2. DNA
On days 7 and 14 there was no difference in DNA between control and Colloss groups. 
On day 21 DNA was significantly higher in Colloss than control cultures. In control 
cultures there was no significant difference in DNA between days 7 and 14. DNA 
decreased significantly between days 14 and 21 (p=0.05) and days 7 and 21 (p=0.05). 
In the Colloss group DNA increased significantly from days 7 to 14 (p=0.050) and 
decreased significantly from days 14 to 21 (p=0.050, Fig.2).
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5.4.3. COLLAGEN TYPE I SYNTHESIS
Procollagen expression on days 7, 14 and 21 was significantly greater on HA pre 
treated with Colloss (p=0.050). In both control and Colloss groups procollagen levels 
peaked on day 21. There was a significant increase in procollagen levels from days 7 to 
14 and 14 to 21 in the Colloss group (p=0.050, Fig.3.).
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5.4.4 Alkaline P hosphatase  Activity
Alkaline Phosphatase activity was significantly higher in control than Colloss cultures 
on day 7 (p=0.05). However, there was no difference between groups on days 14 and 
21. ALP expression increased significantly from day 7 to day 14 to reach peak levels in 
Colloss but not control cultures (p=0.05). In both groups Alkaline Phosphatase 
decreased significantly from days 14 to 21 (p=0.05).
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Fig.4. Alkaline phosphatase with Cobas Bio.
Boxplot of Alkaline phosphatase activity per well standardised for DNA.
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5.4.5. Osteopontin
There was no significant difference in osteopontin expression between Colloss and 
control groups on days 14 and 21. The increase in osteopontin expression between days 
14 and 21 was not significant in Colloss (p=1.000) or control (p=0.127) groups. 
(Fig.5.).
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Fig.5. Boxplot of Osteopontin per culture well, standardised for DNA.
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5.4.6. Cell morphology
On day 21 the control group sample cells were confluent, but maintained an elongated, 
spindle shaped fibroblastic appearance. (Fig.6a and 7a). In contrast, cells cultured on 
the Colloss treated HA granules did not have a spindle shaped morphology but were 
broader, with a polygonal appearance. (Fig.6b and 7b)
Figs 6a-7b: Scanning electron microscopy 21 days after initial seeding of bone marrow 
stromal stem cells onto control and Colloss pre-treated hydroxyapatite granules.
Fig.6a. Day 21 SEM. Control hydroxyapatite granules. Magnification x 200.
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Fig.6b. Day 21. S.E.M. Colloss treated hydroxyapatite 
granules. Magnification x 200.
Fig.7a. Day 21.S.E.M. Control group. 
Magnification X 600.
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Fig. 7b. Day 21 SEM. Colloss treated hydroxyapatite.
Magnification X 600.
5.5. Discussion
The pattern of cell proliferation in both control and Colloss treated HA samples was 
similar for the culture duration with peaks at days 3 and 21. Proliferation rates were 
very similar, with no difference detected until day 21, when control culture 
proliferation rates were marginally but significantly higher as measured by alamar blue, 
which by measuring the metabolic activity of cell cultures, provides an indirect 
measure of cellular proliferation.
Total DNA levels did not differ between groups until day 21 when total DNA was 
greater in the Colloss group. Assuming that the amount of DNA per cell is constant, 
this would suggest a greater number of cells in the Colloss cultures on day 21. Previous 
in vitro studies have demonstrated that HA supports the osteogenic differentiation of 
bone marrow stromal stem cells. Ohgushi et al, 1993, implanted HA pre-loaded with 
autologous bone marrow and a control group of HA without bone marrow into 
subcutaneous sites in rats. It was found that pre-loaded HA supported the formation 
of bone and cells expressed bone GLA protein (BGP) mRNA, whereas in non-loaded
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control hydroxyapatite implants significant bone formation was not seen and BGP 
mRNA was not detected.
Hydroxyapatite has been shown to enhance the osteoblastic differentiation of bone 
marrow stromal stem cells cultured in the presence of osteogenic supplements. 
Nordstrom et al, 1999, described the culture of rat marrow cells on hydroxyapatite in 
the presence of osteogenic supplements.26 Cells grown on HA differentiated to form 
mineralised nodules positive for ALP stains, but cells grown on control culture dishes 
were less intensely stained and showed enzyme activity half that of cells grown on HA.
In previous studies, methods of enhancing the osteogenic differentiation of bone 
marrow stromal cells cultured on hydroxyapatite have been investigated. Kim et al 
cultured bone marrow stromal stem cells on HA with and without the addition of 
recombinant Human Bone morphogenic protein 2. Alkaline Phosphatase levels were 
not enhanced by BMP 2, suggesting that’s its ability to stimulate the differentiation of 
stromal stem cells into osteoblasts is limited. Furthermore, osteocalcin, a later marker 
of osteogenesis was not detected throughout die duration of the study period.187
In this study, unlike that of Ohgushi et al 1993 , osteogenic supplements were not
added to cultures to initiate osteoblastic differentiation. We found that Colloss treated 
HA stromal cell cultures showed a peak ALP expression on day 14, however levels 
were no greater than those in control cultures. Osteopontin, a marker of osteogenic 
differentiation usually expressed later than ALP, did not change significantly between 
days 14 and 21 and did not differ in level between the control and Colloss treated 
samples. There was, however, a stepwise increase in procollagen from days 7 to 21, 
levels of which were significantly higher in the Colloss pre-treated HA granules.
The results of this study do not provide conclusive evidence that Colloss can enhance 
the osteoblastic differentiation of stromal stem cells cultures on hydroxyapatite 
granules. The process of osteoblastic differentiation and the formation of osteoid can be
103
divided into three stages: proliferation, matrix maturation and mineralisation. Alkaline 
Phosphatase is expressed early during this process with collagen and osteopontin 
expression occurring later during matrix maturation and mineralisation. Although 
Alkaline Phosphatase was expressed by cells cultured on HA pre-treated with Colloss, 
we did not observe increased levels of Alkaline Phosphatase in the Colloss group 
compared to control cultures, as would be expected during the early stages of culture to 
signify osteoblastic differentiation. Surprisingly Alkaline Phosphatase levels were 
significantly higher in the control group at day 7. Also, Colloss pre-treated 
hydroxyapatite did not enhance the expression of osteopontin, a marker of osteoblastic 
differentiation detected in the latter stages of differentiation. Despite this, a finding 
consistent with the enhancement of extracellular matrix formation and osteoblastic 
differentiation were the levels of collagen type I we observed which increased during 
the culture period to reach levels on average three times those of the control cultures. 
Collagen type I is a component of bone matrix and its presence suggests a positive 
effect of Colloss on the osteoblastic differentiation of bone marrow stromal stem cells. 
Although Collagen type I can also be produced by fibroblasts, the morphological 
features of bone marrow stromal stems cultured for 21 days suggested an osteoblastic 
phenotype, lending further support for the osteoinductive capacity of Colloss.
Summary
Hydroxyapatite pre-treated with Colloss suspension supported the growth of bone 
marrow stromal stem cells. Evidence of the ability of Colloss to enhance osteoblastic 
differentiation was, however, inconclusive as only one of the osteogenic markers, type 
1 collagen synthesis was raised in the Colloss pre-treated hydroxyapatite cultures.
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6. Chapter 4
The Effect of Colloss on the Osseointegration of Titanium
6.1. Introduction
The stability of femoral stem prostheses relies on the stable fixation between the 
implant and host bone. Osseointegration is the process by which host bone grows onto 
implant surfaces to provide stable support. The osseointegration of titanium femoral 
prostheses is important to provide implant stability, limit loosening and improve die 
longevity of total hip replacements. The ability of implants to osseointegrate with host 
bone may be compromised by the presence of bone defects adjacent to the implant at 
the time of surgery. Ibis is more often a problem during revision surgery when bone 
defects may be extensive. In many centres current practice involves packing of bone 
defects with allograft. Unfortunately there are disadvantages associated with the use of 
allograft and therefore research has been undertaken to find alternatives.
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6.2. Aim and Hypothesis
Aim - The aim of this part of my study is to stimulate hone formation within hone gaps 
adjacent to shotblasted titanium implants to enhance osseointegration using Colloss.
Hypothesis - Colloss will enhance hone formation within bone defects adjacent to 
porous titanium implants and promote their osseointegration in a sheep tibia gap model.
6.3. Materials and Methods
Course for intending licensees under the Animals (Scientific Procedures) Act 1986
As a prerequisite for personal license application the author attended a course for 
intending licensees under the Animals (Scientific Procedures) Act 1986.
Personal and project licenses under the animals (Scientific Procedures) Act 1996
A personal license was then obtained after application to the Home Office.
All animal experiments in this study were covered by the existing departmental project 
licence.
6.3.1. Tibia Plug Gap Model
This model was devised to provide a means of inserting cylindrical shotblasted titanium 
implants into the shafts of sheep tibia to create circumferential gaps of 1 and 2mm 
between the implant and cortical bone.
A system was devised to allow accurate concentric placement of cylindrical titanium 
implants into the tibia. Drills were used to make holes in the tibia for placement of 
titanium implants (Fig.l.) To create a 1mm gap between the implant and cortex, a 7mm 
hole was created in the medial cortex using a 7mm diameter drill. A bush of external
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diameter 6.9mm, internal diameter 4.4mm was then placed in the 7mm hole, with the 
distal end resting in the medullary canal on the intact lateral cortical bone. The outer 
borders lying flush against the medial cortical wall. A 4.3mm diameter drill passed 
through the center of the bush with which it lay flush, to drill the lateral cortex.
Figl. Drills and Tap from top to bottom, Tap, 4.3mm diameter drill and 7mm diameter 
drill
This bush was then removed and replaced with a second bush with the same 6.9mm 
external diameter, but an internal diameter of 5.1mm. After tapping the drill hole, a 
cylindrical shot-blasted titanium implant of diameter 5mm, threaded distally, was 
placed in the center of the bush and screwed firmly into the lateral cortex.
To create a 2mm circumferential gap between implant and cortex, a titanium implant 
with a diameter of 3mm in the non-threaded region was used.
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Fig.2. Shotblasted titanium implants
Fig.2. Implant (A) left, 3mm diameter and implant (B), right, (5mm diameter).
All implants were made from titanium 318 (Ti A16 V4, Titanium International Ltd. 
Keys House, Birmingham B33 OSP, UK). Implants were engineered to the specified 
shape at the Centre for Biomedical Engineering, Stanmore Middlesex. Implant B was 
used to create 1mm periprosthetic gaps. The implant is 25mm in length and 5mm
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diameter, threaded in the distal 12mm. A slot was engineered on the proximal circular 
surface to allow engagement of a screwdriver for ease of implant insertion.
Implant A is 25mm in length. The proximal 13mm of the implant is 3mm in 
diameter. The distal 12mm is threaded to engage the lateral cortex and is of diameter 
5mm. As with implant A, there is a slot in the proximal circular surface for engagement 
of a screwdriver. All implants were shot-blasted on the surface of the non-threaded 
region.
Animals
12 female mule breed sheep aged between 2 and 4 years were used. Prior to operation 
sheep were group housed and following surgery sheep were housed in single pens.
6.3.2. Pre-medication and Induction of anaesthesia
All sheep were given pre-medication comprising Rompun 0.4ml (9.328mg) xylazine 
hydrochloride (Bayer pic Animal Health Business Group, Bury St Edmunds, Suffolk ) 
by intramuscular injection. Induction of anaesthesia was achieved by the administration 
of ketamine hydrochloride 180ml and 3mg of midazolam intravenously. Sheep were 
intubated and anaesthesia was maintained with 2% halothane.
6.3.3. Operative Procedure
Sheep were positioned on the right lateral side. The skin of the tibia was shaved and 
prepared with iodine. Drapes were applied to isolate the operative field (Fig.3). 
Antibiotic prophylaxis was administered in the form of lOOmg ceftiofur (Pfizer Ltd, 
Walton Oaks, Surrey, UK) by intramuscular injection (2mls solution).
A longitudinal incision was made along the medial subcutaneous border of the tibia, 
starting approximately 3 cm below the tibial tuberosity, extending distally through skin
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and fascia. A self retaining retractor was used to displace the skin and fascia laterally 
and expose the periosteum. A longitudinal incision was made in the periosteum, which 
was then elevated using a periosteal elevator.
From proximal to distal, four 7.1 mm diameter holes were drilled through the medial 
cortex of the tibia. The first hole was placed approximately 3cm distal to the tibial 
tuberosity. The remaining 3 holes were placed distally to the first one, with a distance 
of 25mm between the centers of each hole. A 4.3 mm hole was then drilled in the 
lateral cortex concentric to the first hole in the medial cortex using a bush as a guide 
(Fig.5). The drill hole in the lateral cortex was then tapped, again using a bush as a 
guide.
Fig 3. Preparation of skin and draping prior to operation
medial aspect of sheep tibia
Copious irrigation of the drill holes with saline was performed to remove bone and 
marrow debris. The operative field was then dried using gauze swabs. Titanium 
implants were inserted into the medial drill hole and screwed into the lateral cortex
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using a screwdriver. Two of each type of implant was inserted to create two 1mm gaps 
and two 2mm gaps (Fig.6).
Fig. 4. Medial aspect of sheep tibia with four 7mm diameter drill holes.
Fig. 5. Drilling of 4.3 mm holes in lateral cortex using bush
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Collagen lyophilisate was inserted into one of the 1mm gaps and one of the 2mm gaps 
between the implant and cortical bone. The remaining two periprosthetic defects were 
left empty and used as controls.
The subcutaneous tissues were approximated with continuous 2-0 vicryl. Skin was 
closed with interrupted 2-0 vicryl sutures. Opsite wound dressing (Smith & Nephew, 
Cambridge, UK) was sprayed onto the wound, which was covered with dry gauze 
which was then secured with a bandage and TED compressive stocking.
Six procedures were performed for each time period of 4 and 8 weeks. The position 
of the pins and their treatments (+/- Colloss) was varied in a rotatory fashion for each 
of the 6 operations. (Two combinations were therefore repeated).
Fig 6. Titanium pins in situ.
3mm (a) and 5mm (b) diameter titanium pins. Colloss placed into gap (c).
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6.3.4. Post operative care
After surgery, animals were housed in single pens. The antibiotic ceftiofur lOOmg was 
administered intramuscularly once a day for 5 days post-operative days.
6.3.5. Harvest of specimens
At 4 and 8 weeks following surgery, sheep were sacrificed by intravenous injection 
with 60mls of phenobarbitone. The tibia were harvested, radiographed and then 
processed for histology.
6.3.6. DEXA Scanning
Bone mineral density (BMD) of tissue within the gap between the titanium implants 
and cortical bone was measured by DEXA using an x-ray bone densometer (Hologic 
model QDR-1000/W, Massachusetts, USA) in the anterior- posterior plane.
2mm peri-prosthetic defects
Bone mineral density was measured in a selected area 0.25 mm from the titanium 
implant for a width of 1mm.
1mm peri-prosthetic defects
BMD was measured in a selected area 0.25mm from the titanium implant for a width of 
0.5mm. BMD of the cortical bone immediately superior and inferior to the 
periprosthetic gap was measured, averaged and used as the control value. The BMD of 
the peri prosthetic defect was expressed as a ratio of this control value. In hoth the 1 
and 2mm defects the above process of selection was performed 6 times for each 
implant and averaged to give a single value.
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6.3.7. Histology
Specimens were fixed in 10% formal saline for 2 weeks and then processed in serial 
changes of alcohol (10%, 30%, 30% , 70%, 90% and 100%) for durations of 1,3,1,1,1, 
and 3 days respectively. Following dehydration in alcohol, specimens were placed in 
chloroform to remove fat from specimens. Four chloroform changes were made over a 
72 hour period. Specimens were then placed in 100% alcohol for a further 4 days. 
Alcohol was changed 3 times during this period.
Specimens were placed in a solution of alcohol 50% / Acrylic resin 50% (LR White 
Resin, London Resin Company, Reading, Berkshire, England) for 72 hours, then 
acrylic resin 100% for lweek under vacuum. Resin was polymerised by the addition of 
LR white accelerator LR White Resin, London Resin Company, Reading, Berkshire, 
England).
Preparation of slides
Specimens within resin were cut in the coronal plane along the length of the implants 
using an EXAKT saw. Specimens were glued onto Perspex slides and ground between 
60-90 um using and EXACT grinding machine before being polished. Slides were 
stained using 1% Toludine Blue in 1% Borax for 15 minutes, followed by Paragon for a 
further 15 minutes. Slides were then left to dry for 24 hours before application of 
coverslips.
114
6.3.8. Scanning electron microscopy. (S.E.M)
Specimens which had previously heen embedded in resin were sectioned through the 
implant in the coronal plane. The specimens were then mounted onto S.E.M. stubs and 
sputter coated with Palladium for 2 minutes to provide a coating of approximately 
15nm. (Emitech K550, Emitech Ltd, South Stour Ave, Ashford, Kent, TN23 7RS). 
S.E.M was performed using a JEOL scanning electron microscope. (JSM-550LV). 
S.E.M Images were saved as BMP (Bitmap) images and then converted to JPEG (Joint 
Picture Experts Group) images. Images were merged using Adobe Photoshop version 7 
software (Adobe Systems Incorporated, USA) to provide a complete image of each 
implant and adjacent cortical bone.
Using Ziess™ image analysis software, the area of the gap between bone and 
titanium implant was measured to a depth of 3mm from the cortical bone surface. The 
presence or absence of bony apposition to the implant surface was also noted.
6.3.9. Statistics
The Kolmogorov -  Smirnov test was used to determine the normality of data. On the 
basis of the Kolmogorov -  Smirnov statistic, it was determined that variable data was 
non-parametric, hence comparisons of bone mineral density and pin gap area were 
compared using the Mann Whitney U test.
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6.4. Results
6.4.1. Bone mineral density within periprosthetic defects
6.4.1.1. Four Week Specimens
4 week group 1mm periprosthetic defects.
Average BMD ratio in the 1mm periprosthetic defects was 0.7142 compared to 0.6644 
in the 1mm defects pre-filled with Colloss. This difference was not significant 
(p=0.485).
4 week group 2mm periprosthetic defects.
Average BMD ratio in the 2mm periprosthetic defects was 0.6431 compared to 0.7621 
in the 2mm defects pre-filled with Colloss. This difference was not significant 
(p=0.310).
6.4.1.2. Eight Week Specimens
8week group 1mm periprosthetic defects.
Average BMD ratio was 0.8154 in the 1mm defects pre-filled with Colloss, compared 
to 0.7561 in the control group. This difference was not significant (p=0.394).
8 week group 2mm periprosthetic defects.
Average BMD ratio was 0.7305 g/cm2 in the 2mm defects pre-filled with Colloss, 
compared to 0.6420 g/cm in the control group. This difference was not significant 
(p=0.240).
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4 weeks vs 8 weeks; 2mm defects.
There was no significant difference in BMD ratio between the 4 and 8 week time 
periods for 2mm Colloss (p=1.0) or the 2mm control group (p=0.873).
4 weeks vs 8 weeks; 1mm defects
There was no significant difference in BMD ratio between the 4 and 8 week time 
periods for 1mm Colloss (p=0.150) or the 1mm control group (p=0.423).
B one M inera l Density 
2m m  defects
Q 0.4-
0 .0 -  «'
4 weeks 8 weeks
Time
Control
Colloss
Fig.7. Mean bone mineral density within 2mm periprosthetic defects. Four and eight 
week specimens. BMD Expressed as a ratio of BMD of bone adjacent to defect. 
Error bars represent +/-1 standard error of the mean
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Bone M in era l D ensity 
lm m  defects
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o .o -  -----------
4 weeks 8 weeks
Time
■  Control
■  Colloss
Fig.8. Mean bone mineral density within lmm periprosthetic defects. Four and eight 
week specimens. BMD Expressed as a ratio of BMD of bone adjacent to defect.
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6.4.2. Bone formation within Periprosthetic defects
The area of periprosthetic defects at four and eight weeks is shown in fig.9.
6.4.2.1. Four week specimens
lmm and 2mm defects.
At 4 weeks there was no significant difference in the periprosthetic gap area between 
lmm control and Colloss groups. (p=0.522) (Figs. 10a, b and 11). There was also no 
significant difference in the periprosthetic gap area between the 2mm Colloss and 2mm 
control groups (p=1.000) (figs 12 and 13).
lmm vs 2mm defects.
At 4 weeks there was no significant difference in the periprosthetic gap area between 
the lmm Colloss and the 2 mm control groups (p=0.055).
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Area of periprosthetic defect 
Colloss vs Control
[~ 1 1 mm
1 1 mm colloss 
□  2mm  
I 12mm Colloss
4 weeks 8 weeks
Fig.9. Boxplot of Periprosthetic defect area adjacent to titanium implants.
There was no significant difference in the periprosthetic gap between the lmm and 
2mm Colloss specimens (p=0.055). At 4 weeks the lmm control group had 
significantly lower periprosthetic gap areas than the 2mm control group (p=0.025). 
There was no difference in the 2mm Colloss group and the lmm control group at 4 
weeks.
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Figures 10-17. Scanning electron microscopy of Titanium implants in coronal 
section.
a b
Fig.lOa and b. 4 week specimens lmm periprosthetic defect control
Fig. 11. 4 week specimen, lmm defect with Colloss
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Fig. 13a and b. 4 weeks. 2mm periprosthetic defect with Colloss
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6.4.2.2. Eight week specimens 
1mm and 2 mm defects.
At 8 weeks the peri implant gap was 2,548,695um2 in the 1mm control group and 
l,114,150um in the 1mm Colloss group, but the difference was not significant 
(p=1.000, Figs 14 and 15). At 8 weeks there was no difference in peri-implant gap area 
between the 2mm control and Colloss specimens. (p=1.000, Figs 16 and 17).
1mm vs 2mm defects.
At 8 weeks there was no difference in peri-implant gap area between the 1 and 2 mm 
control groups (p=0.337). There was no difference in peri-implant gap area between the 
2mm Colloss specimens and the 1mm control group gap area at 8 weeks (p=0.423).
There was no difference in peri-implant gap area between the 1mm Colloss group 
and the 2mm control group at 8 weeks (p=0.109). There was also no difference in peri- 
implant gap area between the 1mm Colloss and 2mm Colloss groups at 8 weeks 
(p=0.078).
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Fig. 14a and b. 8 week specimen. 1mm periprosthetic defect control
Fig. 15a and b. 8 week specimens. 1mm periprosthetic defect with Colloss
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a b
Fig.l6.a and b. 8 week specimens. 2mm periprosthetic defects control 
group
Fig.l7a and b. 8 week specimens. 2mm defects with Colloss
Note, in the Colloss containing specimen, (a). New bone formation with obliteration of 
gap on left. On the right is poorly mineralised new bone formation in close apposition 
to titanium implant.
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6.4.2.3. Four week vs eight week specimens
There was no difference in peri-implant gap area in the 1mm control groups between 4 
and 8 weeks (p=0.055). However, there was a significant reduction in the peri-implant 
gap area between the 1mm Colloss 4 and 8 week specimens (p=0.004).
There was a significant reduction in peri-implant gap area in the 2mm control 
specimens between 4 and 8 weeks (p=0.004). There was also a significant reduction in 
peri-implant gap area in the 2mm Colloss specimens between 4 and 8 weeks (p=0.016).
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6.4.3. Descriptive Histology
6.4.3.1. Undecalcified Histology. 4 week Specimens
a h
Fig. 18a (control) and b(CoIloss). Histology. 4 week specimen. 1mm 
periprosthetic defects. Stained with paragon and toluidine blue at the level of 
tibia cortex. There is immature woven bone formation in both the control and 
Colloss specimens. This lies in contact with the old mature lamellar bone(CB). 
In both groups the woven bone is separated from the titanium implant surface 
(Black region to right of picture) by interposition of fibrous tissue(FT)
aFig.l9a(control) and b(Colloss). 4 week specimens with 2mm periprosthetic defects. 
Woven bone has formed in the control sample, in direct contact with old lamellar 
bone. Fibrous tissue is seen between the new bone and implant surface (FT).
In the Colloss specimen, woven bone appears to surround an area of fibrous type 
tissue (FT) lying adjacent to the titanium prosthetic surface. It is possible that this 
represents a remnant of the implanted Colloss.
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6.4.3.2. Undecalcified histology 8 week specim ens
Fig.20a(control) and b(Colloss). 8 week specimens with 1mm periprosthetic 
defects. The bone filling the defects has matured in both specimens. The woven 
bone noted in 4 weeks specimen has been partially replaced by lamellar bone in 
which Haversian systems have formed. Bone in close relationship to titanium 
implant, but in both control and Colloss remain separated by a thin layer of fibrous 
tissue (Arrows)
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cFig.21. a(control), b+c(Colloss). 8 week specimens with 2mm defect. Immature 
woven bone is present in both control (a) and Colloss specimens (c). There 
remains a gap between implant and bone.
In specimen (b) which contained Colloss, bone has matured and partially 
remodelled. This bone lies in close relationship with the implant prosthesis 
(arrows).
In specimen (c) which contains Colloss there appears to be fibrous type tissue 
between the new bone trabeculae and the implant surface. This may represent 
remnants of the Colloss implanted at the time of surgery. Alternatively it may 
represent fibrous tissue forming secondary to the hosts response to the procedure.
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6.5. Discussion
The fixation of uncemented intramedullary stems used in joint arthroplasty relies on 
their secure fixation to bone. Osseointegration with the ingrowth of bone onto implant 
surfaces is important to achieve such fixation. The osseointegration of titanium press fit 
and screw implants in humans and animals has been examined by investigators in 
previous studies.188,189,190,191 In these studies direct bone to implant contact was evident 
in retrieval specimens. Although uncemented hip replacements are implanted with an 
interference fit, it is likely that periprosthetic gaps remain, particularly following 
revision surgery where bone loss is inevitable. Methods of enhancing peri-implant bone 
formation to obliterate such gaps and promote osseointegration will improve implant 
stability.
Therefore, in this study we have investigated the formation of bone adjacent to non­
load bearing titanium implants using a gap model and examined the effects of Colloss 
on the process of bone ingrowth. The results obtained from the experiments described 
did not provide evidence to support the study hypothesis. Compared to the control 
groups Colloss did not enhance the formation of bone within periprosthetic defects, nor 
did it enhance the osseointegration of titanium implants.
The bone mineral density measurements of the tissue within the periprosthetic 
defects were consistently greater in the Colloss specimens for 1 and 2 mm gap defects 
at four and eight weeks. However, a significant difference was not observed. It is 
possible that differences in bone mineral density would have become evident if the 
implant was left in situ for a longer period of time.
The presence of Colloss in the periprosthetic defects did not appear to have any 
deleterious effects on the formation of bone within the defects. New woven bone was 
evident in both groups at 4 weeks, and by 8 weeks there was no significant difference 
in the peri-implant gap area between the 1mm and 2mm defects. Eight week defects in
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the 1mm Colloss specimens were on average less than those of the control group, but 
this differerence was not significant. In all cases where new woven bone formation was 
observed it formed in continuation with the host bone in the defect, towards the implant 
surface. Bone formation was not initiated at the titanium implant surface, nor did it 
appear to form de novo within the periprosthetic defect in any of the specimens 
observed.
The presence of Colloss in 1mm defects did, however, result in a significant 
reduction in the size of defects’ area from the four to eight week time periods. This 
difference between four and eight week 1mm defect specimens was not observed in the 
control group. In the majority of specimens, both control and Colloss, a gap was 
discemable between the implant and host bone. This often contained fibrous tissue.
In some of the Colloss containing specimens there was fibrous type tissue, adjacent to 
which were the prominent trabeculae of newly formed bone. We were unable to 
determine the precise nature of this tissue, but it is plausible that it comprises residual 
Colloss. If this tissue represents Colloss, this may prove to be detrimental by acting as a 
physical barrier to bone ingrowth. However, this did not become apparent during the 
eight week duration of the study. In contrast to previous reports of the osseointegration 
of press fit implants, contact between bone and implant was unusual in this gap model 
for the study duration. There appeared to be direct contact of new bone with the 
implant in only one specimen. In this case a 2mm gap had been pre-filled with Colloss 
and at eight weeks there was a layer of poorly mineralised bone covering the shot 
blasted titanium implant surface.
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Summary
The presence of Colloss within the periprosthetic gap did not enhance bone formation 
or increase bone mineral density within 1 or 2 mm defects adjacent to shotblasted 
titanium implants at 4 and 8 weeks following implantation.
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7.Chapter 5
General Discussion
The determination of the precise mechanisms of action of Colloss on the growth and 
differentiation of bone marrow stromal stem cells was beyond the scope of this study. 
The aims of this study were to establish the effects of Colloss on the behaviour of 
BMSSCs in vitro and its effect on bone formation in vivo.
Colloss contains an abundance of collagen type 1 as well as bone matrix proteins, 
both of which are conducive to the osteogenic process. Bone matrix contains a 
repertoire of proteins which are involved in the cascade of bone formation. Type one 
collagen, of which there is an abundance in Colloss, may also have an important role in 
the osteogenic process. Type one collagen molecules are released from cells as a pro 
collagen which is then activated extracellularly by cleavage of the carboxy terminal pro 
peptide. Two thirds of the amino acids are glycine, proline and hydroxyproline. 
Collagen molecules then combine to form a triple helix, consisting of 2 alpha and one 
beta chain, which form a right handed triple helix. Glycine is present at every third 
position, which is important to maintain the helix structure.
Collagen type I is the most abundant protein within the organic matrix of bone, of 
which it represents 90%. The remaining 10% is comprised of osteocalcin, osteonectin, 
glycosaminoglycans and lipids. It has a role not only in maintaining the structural 
integrity of bone, but also has effects on cell behaviour during bone formation. It is not 
only osteoconductive, but can also bind growth factors which are involved in the 
process of osteogenesis192. It also has binding sites for osteonectin and osteocalcin, 
which in turn can bind calcium allowing initiation of the mineralisation process.193,194 
Collagen also has the RGD sequence of amino acids (Arg-Gly-Asp) which interact with 
the CD44 cell surface receptors allowing interaction between collagen and cells of the 
extra cellular matrix.195 Collagen has osteoconductive properties. Collagen based
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implants have been used alone or in combination with autologous bone graft, where 
they have been shown to stimulate bone formation in animal spinal fusion and critical 
gap defect models.196,197 In addition to the RGD sequence, collagen has a DGEA cell 
binding domain comprising the amino acid sequence Asp-Gly-Glu-Ala. In animal 
studies there is evidence that interactions between bone marrow stromal stem cell 
surface integrins and the DGEA collagen domain can stimulate the osteoblastic 
differentiation of these cells.
Muzino et al,147 examined the behaviour of collagen type I on rat bone marrow cells 
and the effects of blocking interactions between the alpha 2 beta 1 integrin and 
collagen. The presence of collagen type 1 stimulated the osteoblastic differentiation of 
these cells, signified by the expression of Alkaline Phosphatase, osteocalcin, 
osteopontin and the synthesis of collagen type 1. In contrast, cells cultured without 
collagen type 1 did not undergo osteoblastic differentiation. When the cell integrin 
receptors were blocked by the addition of DGEA peptide (the cell binding domain of 
collagen), the osteoblastic differentiation of bone marrow cells was Inhibited. 
Furthermore, the addition of antibodies to block the alpha 2 integrin also inhibited the 
osteoblastic differentiation of cells. This suggests that collagen -  integrin interactions 
play an important role in the mediation of extracellular signals required for the 
differentiation of bone marrow stromal stem cells.
The role of collagen type I on osteogenesis was examined in a further study by 
Takeuchi et al198 who investigated the effects of collagen type one on TGF p receptors 
and ALP expression on rat bone marrow stem cells. The expression of Alkaline 
Phosphatase in osteoblasts was inhibited by TGF p in long term cultures. It was shown 
that collagen increased ALP activity in cultures by down regulating TGF p receptors, 
and that this effect was mediated via the alpha 1, beta 2 integrin. It was also found that 
collagen fibrils synthesised by the osteoblasts contributing to the formation of
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extracellular matrix had the same effect as exogenous collagen on TGF beta receptors, 
resulting in enhancement of ALP expression. Despite these results it remains unclear 
whether such mechanisms are applicable to human bone marrow stromal stem cells.
Although Colloss consists mainly of collagen type I, it is also derived from bone 
matrix which contains several growth factors in low concentration. These include TGF- 
p, IGF, IL-1, IL6, PDGF, CSF, TNFa, PG’s and bone morphogenic proteins. Whilst it 
is feasible that these factors may have influenced bone marrow stromal stem cell 
behaviour in vitro, it is unclear as to whether the manufacturing processes performed 
during the production of Colloss impair, or perhaps even inactivate, these growth 
factors.
Colloss influenced the expression of osteogenic differentiation markers when 
cultured on hydroxyapatite, titanium and monolayer cultures. Some, but not all, of the 
osteogenic markers were elevated. With stem cells cultured in monolayer, Colloss 
stimulated the mineralisation of cultures, evidenced by increased calcium content. In 
this study we chose concentrations of Colloss of 1:100 and 1:50 dilution. Is is possible 
that for stimulation of osteoblastic differentiation these concentrations are suboptimal.
When bone marrow stromal stem cells were cultured on titanium, observation of the 
early peak in Alkaline Phosphatase and increased osteopontin expression on days 14 
and 21 supports the hypothesis that Colloss has osteogenic properties. However, in this 
experiment, the synthesis of collagen type I was not enhanced by die pre-treatment of 
titanium with Colloss.
When cultured on hydroxyapatite, Colloss lead to an increase in collagen type I 
synthesis, but not Alkaline Phosphatase or osteopontin when compared to controls. 
Collagen type 1 expression is not specific to osteoblasts as fibroblasts can also express 
large amounts of collagen type 1 in vitro. However cell cultures in this study can be 
distinguished from fibroblastic cultures by their osteogenic marker profiles. Whilst
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collagen type 1 can be expressed both by fibroblasts and osteoblasts, proteins with a 
role in the mineralization phase of osteogenesis such as osteopontin are not expressed 
or are expressed in negligible amounts by fibroblasts.199
A weakness of this study was the small sample number (n) in the cell culture studies 
and the use of non parametric statistics which was necessitated by the non normal 
distribution of the data. Both these factors reduce the power of the study to determine 
differences in osteogenic marker expression between culture groups and within groups 
at different time periods.
Despite these observations, when implanted in vivo within periprosthetic gaps 
adjacent to titanium implants, Colloss did not appear to enhance the quantity of bone 
formation during the 8 weeks prior to implant harvest. The Colloss was, however, 
biocompatible and did not appear to cause any adverse effects.
Bone marrow contains a mixed population of cells, including committed 
osteoprogenitors. To ensure the validity of results it is important to ensure that 
contamination of stromal stem cell isolates with progenitors is minimised. In this study 
we used methods of stem cell harvest and isolation which are well documented in the 
literature122,78. Ficoll was used to separate bone marrow stromal stem cells from bone 
marrow using a density gradient technique. Using antibodies to STRO-1 we were able 
to confirm that we had obtained a population of bone marrow stromal stem cells. 
Although cell sorting devices were not used, by labelling cells with stro -1 with 
indirect immunofluorescence, we were able to confirm that cell isolates comprised 
stromal stem cells. Is is possible that progenitors may have been present within isolates, 
but the number is likely to be proportionally insignificant. Furthermore, stem cells used 
for control and experimental groups were derived from the same primary isolate, hence 
minimising the risk of bias.
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7.1. Conclusions
Colloss does not enhance bone formation or increase mineral content of new bone 
within defects adjacent to non-loaded titanium implants in a sheep gap model. Colloss 
suspension appears to have an effect on the expression of osteogenic markers by bone 
marrow stromal stem cells cultured in monolayer, smooth polished titanium and 
hydroxyapatite granules. In each case, some but not all of the osteogenic markers were 
expressed at levels above those of the control group. Therefore, with regards to cell 
culture in vitro, the results, although supportive of the osteogenic potential of Colloss, 
are inconclusive.
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7.2. Further work
It is likely that the influence of Colloss on growth arid differentiation of hone marrow 
stromal stem cells is concentration dependent. The optimal concentration of Colloss to 
stimulate cell differentiation is unknown. Further study of the effects of Colloss at 
various concentrations on stem cell behaviour may allow this to he determined.
Further information on the effects of Colloss on the expression by BMSSCs of 
mRNA’s which encode for osteogenic markers such as osteocalcin, osteopontin, bone 
sialoprotein and osteonectin, could be obtained by utilising RT PCR techniques. This 
would allow quantification of gene expression and determination of the sequence of 
gene expression, allowing direct comparison with control cultures.
Colloss did not appear to enhance bone formation within periprosthetic defects In 
this study. It would be of interest to determine whether it can stimulate bone formation 
in the absence of bone defects. This could be assessed by applying Colloss to press fit 
titanium implants
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